View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2012	Feb. 28, 2013	Jun. 29, 2012
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY
Trading Symbol	DVAX
Entity Registrant Name	DYNAVAX TECHNOLOGIES CORP
Entity Central Index Key	0001029142
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		182,881,013
Entity Public Float			$ 422,877,457

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 7,599	$ 31,941
Marketable securities available-for-sale	117,531	82,020
Accounts receivable	1,005	9,527
Prepaid expenses and other current assets	2,052	1,130
Total current assets	128,187	124,618
Property and equipment, net	7,965	6,163
Goodwill	2,475	2,312
Restricted cash	652	647
Other assets	473	362
Total assets	139,752	134,102
Current liabilities:
Accounts payable	2,166	2,040
Accrued liabilities	10,063	8,159
Deferred revenues	6,785	4,210
Note payable to Symphony Dynamo Holdings LLC ("Holdings")		12,810
Total current liabilities	19,014	27,219
Deferred revenues, noncurrent	5,283	6,386
Other long-term liabilities	629	617
Total liabilities	24,926	34,222
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock: $0.001 par value; 5,000 shares authorized and no shares issued and outstanding at December 31, 2012 and 2011
Common stock: $0.001 par value; 250,000 shares authorized at December 31, 2012 and 2011, respectively; 182,792 and 154,626 shares issued and outstanding at December 31, 2012 and 2011, respectively	183	155
Additional paid-in capital	550,729	466,276
Accumulated other comprehensive loss:
Unrealized gain (loss) on marketable securities available-for-sale	45	(3)
Cumulative translation adjustment	(640)	(1,006)
Total accumulated other comprehensive loss	(595)	(1,009)
Accumulated deficit	(435,491)	(365,542)
Total stockholders' equity	114,826	99,880
Total liabilities and stockholders' equity	$ 139,752	$ 134,102

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2012	Dec. 31, 2011
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000	250,000
Common stock, shares issued	182,792	154,626
Common stock, shares outstanding	182,792	154,626

Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Collaboration revenue	$ 4,610	$ 17,190	$ 19,535
Grant revenue	3,939	3,110	3,940
Service and license revenue	1,165	1,314	475
Total	9,714	21,614	23,950
Operating expenses:
Research and development	49,146	51,322	53,680
General and administrative	28,164	17,570	16,879
Amortization of intangible assets		299	980
Total operating expenses	77,310	69,191	71,539
Loss from operations	(67,596)	(47,577)	(47,589)
Interest income	291	103	85
Interest expense	(2,351)	(1,957)	(1,654)
Other income (expense)	(293)	834	(8,150)
Net loss	$ (69,949)	$ (48,597)	$ (57,308)
Basic and diluted net loss per share	$ (0.41)	$ (0.39)	$ (0.69)
Shares used to compute basic and diluted net loss per share	170,469	125,101	82,463

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Net loss	$ (69,949)	$ (48,597)	$ (57,308)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities available-for-sale	48	14	(17)
Cumulative translation adjustment	366	(277)	(561)
Total other comprehensive income (loss)	414	(263)	(578)
Total comprehensive loss	$ (69,535)	$ (48,860)	$ (57,886)

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

- Definition

Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Consolidated Statements Of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss )	Accumulated Deficit
Beginning Balances (in shares) at Dec. 31, 2009		54,279
Beginning Balances at Dec. 31, 2009	$ 6,376	$ 54	$ 266,127	$ (168)	$ (259,637)
Issuance of common stock upon exercise of stock options and restricted stock awards (In Shares)		141
Issuance of common stock upon exercise of stock options and restricted stock awards	160	$ 1	159
Issuance of common stock under Employee Stock Purchase Plan (in shares)		121
Issuance of common stock under Employee Stock Purchase Plan	72		72
Proceeds from issuances of common stock and warrants, net of issuance costs (in shares)		59,994
Proceeds from issuances of common stock and warrants, net of issuance costs	87,399	$ 59	87,340
Reclassification of the warrant liability to Holdings into equity and the impact of the anti-dilution provision associated with the common stock and warrants issued to Holdings (in shares)		1,076
Reclassification of the warrant liability to Holdings into equity and the impact of the anti-dilution provision associated with the common stock and warrants issued to Holdings	13,580	$ 2	13,578
Stock compensation expense	2,410		2,410
Total comprehensive income (loss)	(578)			(578)
Net loss	(57,308)				(57,308)
Ending Balances (in shares) at Dec. 31, 2010		115,611
Ending Balances at Dec. 31, 2010	52,111	$ 116	369,686	(746)	(316,945)
Issuance of common stock upon exercise of stock options and restricted stock awards (In Shares)		308
Issuance of common stock upon exercise of stock options and restricted stock awards	10		10
Issuance of common stock under Employee Stock Purchase Plan (in shares)		106
Issuance of common stock under Employee Stock Purchase Plan	132		132
Proceeds from issuances of common stock and warrants, net of issuance costs (in shares)		38,601
Proceeds from issuances of common stock and warrants, net of issuance costs	91,298	$ 39	91,259
Stock compensation expense	5,189		5,189
Total comprehensive income (loss)	(263)			(263)
Net loss	(48,597)				(48,597)
Ending Balances (in shares) at Dec. 31, 2011		154,626
Ending Balances at Dec. 31, 2011	99,880	$ 155	466,276	(1,009)	(365,542)
Issuance of common stock upon exercise of stock options and restricted stock awards (In Shares)		1,222
Issuance of common stock upon exercise of stock options and restricted stock awards	1,955	$ 1	1,954
Issuance of common stock under Employee Stock Purchase Plan (in shares)		141
Issuance of common stock under Employee Stock Purchase Plan	307		307
Proceeds from issuances of common stock and warrants, net of issuance costs (in shares)		26,803
Proceeds from issuances of common stock and warrants, net of issuance costs	71,780	$ 27	71,753
Stock compensation expense	10,439		10,439
Total comprehensive income (loss)	414			414
Net loss	(69,949)				(69,949)
Ending Balances (in shares) at Dec. 31, 2012		182,792
Ending Balances at Dec. 31, 2012	$ 114,826	$ 183	$ 550,729	$ (595)	$ (435,491)

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Operating activities
Net loss	$ (69,949)	$ (48,597)	$ (57,308)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,207	1,303	1,415
Amortization of intangible assets		299	980
Loss (gain) on disposal of property and equipment	8	20	(36)
Accretion of discounts and amortization of premiums of marketable securities	1,298	1,172	367
Interest associated with long-term note payable to Holdings	2,190	1,871	1,597
Fair value adjustment of the warrant and contingent liabilities to Holdings, including the impact of the anti-dilution provision associated with the common stock and warrants issued to Symphony Capital Partners, L.P. and Symphony Strategic Partners, LLC (collectively, "Symphony")		(843)	8,816
Stock compensation expense	10,439	5,189	2,410
Changes in operating assets and liabilities:
Accounts receivable	8,522	(8,526)	(106)
Prepaid expenses and other current assets	(922)	230	(774)
Restricted cash and other assets	(116)	(290)	(38)
Accounts payable	126	(289)	643
Accrued liabilities and other long term liabilities	1,916	(2,167)	3,381
Deferred revenues	1,472	3,512	(12,717)
Net cash used in operating activities	(43,809)	(47,116)	(51,370)
Investing activities
Purchases of marketable securities	(206,149)	(111,205)	(80,835)
Proceeds from maturities of marketable securities	169,387	77,729	30,750
Purchases of property and equipment, net	(2,931)	(1,142)	(420)
Net cash used in investing activities	(39,693)	(34,618)	(50,505)
Financing activities
Proceeds from issuances of common stock and warrants, net of issuance costs	71,780	91,298	87,399
Proceeds from exercise of stock options and restricted stock awards	1,955	10	160
Proceeds from employee stock purchase plan	307	132	72
Payment of notes payable to Holdings	(15,000)
Net cash provided by financing activities	59,042	91,440	87,631
Effect of exchange rate on cash and cash equivalents	118	(218)	(23)
Net increase (decrease) in cash and cash equivalents	(24,342)	9,488	(14,267)
Cash and cash equivalents at beginning of year	31,941	22,453	36,720
Cash and cash equivalents at end of year	7,599	31,941	22,453
Non-cash investing and financing activities:
Warrants issued in conjunction with the SDI transaction			6,638
Disposal of fully depreciated property and equipment	169	1,181	42
Net change in unrealized gain (loss) on marketable securities	$ 48	$ 14	(17)
Aspire Capital purchase agreement
Non-cash investing and financing activities:
Shares issued			1,200
SDI transaction
Non-cash investing and financing activities:
Shares issued			$ 1,551

Organization

12 Months Ended

Dec. 31, 2012

Organization

1. Organization

Dynavax Technologies Corporation (“we,” “our,” “us,” Dynavax” or the “Company”), a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Our lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine.

Our pipeline of product candidates includes: HEPLISAV, our autoimmune program partnered with GlaxoSmithKline (“GSK”) and our therapy for asthma partnered with AstraZeneca AB (“AstraZeneca”). We compete with pharmaceutical companies, biotechnology companies, academic institutions and research organizations in developing therapies to prevent or treat infectious and inflammatory diseases. Our product candidates are based on the use of immunostimulatory sequences (“ISS”) and immunoregulatory sequences. We were incorporated in California in August 1996 under the name Double Helix Corporation, and we changed our name to Dynavax Technologies Corporation in September 1996. We reincorporated in Delaware in 2000.

Subsidiaries

In April 2006, we completed the acquisition of Rhein Biotech GmbH (“Rhein” or “Dynavax Europe”), a wholly-owned subsidiary in Düsseldorf, Germany. In October 2011, we formed Dynavax International, B.V., a wholly-owned subsidiary in Amsterdam, Netherlands.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2012

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include our accounts and those of our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. We operate in one business segment, which is the discovery and development of biopharmaceutical products. We determine our segments based on the way we organize our business by making operating decisions and assessing performance. In fiscal years 2012, 2011 and 2010, 88%, 94% and 98% of our revenues were earned in the United States, respectively, and the remaining revenues were earned in Germany. As of December 31, 2012, and 2011, 10% and 14%, respectively, of our long-lived assets were located in the United States and the remaining long-lived assets were located in Germany.

Liquidity and Financial Condition

We have incurred significant operating losses and negative cash flows from operations since our inception. As of December 31, 2012, we had cash, cash equivalents and marketable securities of $125.1 million. We currently estimate that we have sufficient cash resources to meet our anticipated cash needs through at least the next 12 months based on cash, cash equivalents and marketable securities on hand as of December 31, 2012 and anticipated revenues and funding from existing agreements.

If we are unable to generate significant revenues from HEPLISAV, if it is approved, and to continue development of our product candidates, we may need to raise additional funds. This may occur through strategic alliance and licensing arrangements and/or future public or private financings. Sufficient additional funding may not be available on acceptable terms, or at all. Additional equity financings, if completed, could result in significant dilution or otherwise adversely affect the rights of existing shareholders. If adequate funds are not available in the future, we may need to delay, reduce the scope of or put on hold the HEPLISAV program or our other development programs while we seek strategic alternatives.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from these estimates.

Foreign Currency

We consider the local currency to be the functional currency for our international subsidiary, Rhein. Accordingly, assets and liabilities denominated in foreign currencies are translated into U.S. dollars using the exchange rate on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing throughout the year. Currency translation adjustments are charged or credited to accumulated other comprehensive income (loss) in the consolidated balance sheets. For the years ended December 31, 2012, 2011 and 2010, we reported an unrealized gain of $0.4 million, an unrealized loss of $0.3 million and an unrealized loss of $0.6 million, respectively. Realized gains and losses resulting from currency transactions are included in the consolidated statements of operations. For the years ended December 31, 2012, 2011 and 2010, we reported a loss of $0.2 million, a gain of $0.2 million and a loss of $0.1 million, respectively, resulting from currency transactions in our consolidated statements of operations.

Cash, Cash Equivalents and Marketable Securities

We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Management determines the appropriate classification of marketable securities at the time of purchase. We invest in short-term money market funds, U.S. government agency securities, U.S. treasury securities, municipal securities and corporate obligations secured by the Federal Deposit Insurance Corporation through the Temporary Liquidity Guarantee Program. We believe these types of investments are subject to minimal credit and market risk. We do not invest in auction rate securities or securities collateralized by home mortgages, mortgage bank debt, or home equity loans.

We have classified our entire investment portfolio as available-for-sale. We view our available-for-sale portfolio as available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities with unrealized gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses and declines in value, if any, judged to be other than temporary on available-for-sale securities are included in interest income or expense. The cost of securities sold is based on the specific identification method. Management assesses whether declines in the fair value of investment securities are other than temporary. In determining whether a decline is other than temporary, management considers the following factors:

•

Whether the investment has been in a continuous realized loss position for over 12 months;

•

the duration to maturity of our investments;

•

our intention to hold the investments to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost bases;

•

the credit rating, financial condition and near-term prospects of the issuer; and

•

the type of investments made.

To date, there have been no declines in fair value that have been identified as other than temporary.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable. Our policy is to invest cash in institutional money market funds and marketable securities of U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including money market funds, U.S. government agency securities, U.S. treasury securities and municipal securities secured by the Federal Deposit Insurance Corporation through the Temporary Liquidity Guarantee Program. We do not invest in auction rate securities or securities collateralized by home mortgages, mortgage bank debt, or home equity loans. We have not experienced any losses on our cash equivalents and marketable securities.

Accounts receivable are recorded at invoice value. We review our exposure to accounts receivable, including the potential for allowances based on management’s judgment. We have not historically experienced any significant losses. We do not currently require collateral for any of our trade accounts receivable.

Our future products will require approval from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay of such approvals would have a material adverse impact on our business.

We have relied on a limited number of suppliers to produce ISS for clinical trials and a single contract manufacturer to produce our first generation ISS, 1018 (“1018 ISS”) for HEPLISAV. The loss of our current supplier would have a significant effect on our ability to produce HEPLISAV for commercialization and development of our other product candidates. To date, we have manufactured only small quantities of ISS and 1018 ISS ourselves for development purposes.

We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishing appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of our stock price and the need to obtain additional financing.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repair and maintenance costs are charged to expense as incurred. Leasehold improvements in both of our facilities are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.

Valuation of Long-Lived Assets and Intangible Assets

We evaluate the carrying value of long-lived assets, including intangible assets, whenever events or changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. Intangible assets were subject to amortization and amortized over their estimated period of benefit of five years. When an indicator of impairment exists, long-lived assets are written down to their respective fair values. Fair value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved. Significant management judgment is required in the forecast of future operating results that is used in the preparation of expected undiscounted cash flows. No impairments of purchased intangible assets have been identified during the years presented.

Goodwill

Our goodwill balance relates to our April 2006 acquisition of Rhein. Goodwill was recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value, by applying the acquisition method of accounting. Goodwill is not amortized but is subject to an annual impairment test which consists of a comparison of the fair value of the related reporting unit against its carrying amount including goodwill. If the carrying amount exceeds the fair value, impairment is calculated and recorded as a charge in the consolidated statements of operations. We determined that we have only one operating segment and there are no components of that operating segment that are deemed to be separate reporting units such that we have one reporting unit for purposes of our goodwill impairment testing. We evaluate goodwill for impairment on an annual basis and on an interim basis if events or changes in circumstances between annual impairment tests indicate that the asset might be impaired.

Revenue Recognition

Our revenues consist of amounts earned from collaborations, grants and fees from services and licenses. We enter into license and manufacturing agreements and collaborative research and development arrangements with pharmaceutical and biotechnology partners that may involve multiple deliverables. Our arrangements may include one or more of the following elements: upfront license payments, cost reimbursement for the performance of research and development activities, milestone payments, other contingent payments, contract manufacturing service fees, royalties and license fees. Each deliverable in the arrangement is evaluated to determine whether it meets the criteria to be accounted for as a separate unit of accounting or whether it should be combined with other deliverables. We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured.

On January 1, 2011, we adopted on a prospective basis Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2009-13, Multiple-Deliverable Revenue Arrangements, which amends the criteria related to identifying separate units of accounting and provides guidance on whether multiple deliverables exist, how an arrangement should be separated and the consideration allocated.

Non-refundable upfront fees received for license and collaborative agreements entered into prior to January 1, 2011 and other payments under collaboration agreements where we have continuing performance obligations related to the payments are deferred and recognized over our expected performance period. Revenue is recognized on a ratable basis, unless we determine that another methodology is more appropriate, through the date at which our performance obligations are completed. Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include clinical development activities. Given the uncertainties of research and development collaborations, significant judgment is required to determine the duration of the performance period. We recognize cost reimbursement revenue under collaborative agreements as the related research and development costs are incurred, as provided for under the terms of these agreements.

On January 1, 2011, we elected to prospectively adopt the milestone method as described in FASB ASU 2010-17, Milestone Method of Revenue Recognition. Under the milestone method, contingent consideration received from the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is defined as an event having all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, (ii) the event can only be achieved based in whole or in part on either the entity’s performance or a specific outcome resulting from the entity’s performance and (iii) if achieved, the event would result in additional payments being due to the entity.

Our license and collaboration agreements with our partners provide for payments to be paid to us upon the achievement of development milestones. Given the challenges inherent in developing biologic products, there is substantial uncertainty whether any such milestones will be achieved at the time we entered into these agreements. In addition, we evaluate whether the development milestones meet the criteria to be considered substantive. The conditions include: (i) the development work is contingent on either of the following: (a) the vendor’s performance to achieve the milestone or (b) the enhancement of the value of the deliverable item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) it relates solely to past performance and; (iii) it is reasonable relative to all the deliverable and payment terms within the arrangement. As a result of our analysis, we consider our development milestones to be substantive and, accordingly, we expect to recognize as revenue future payments received from such milestones as we achieve each milestone.

Milestone payments that are contingent upon the achievement of substantive at-risk performance criteria are recognized in full upon achievement of those milestone events in accordance with the terms of the agreement and assuming all other revenue recognition criteria have been met. All revenue recognized to date under our collaborative agreements has been nonrefundable.

Our license and collaboration agreements with certain partners also provide for contingent payments to be paid to us based solely upon the performance of our partner. For such contingent payments we expect to recognize the payments as revenue upon receipt, provided that collection is reasonably assured and the other revenue recognition criteria have been satisfied.

Revenues from manufacturing services are recognized upon meeting the criteria for substantial performance and acceptance by the customer.

Revenue from royalty payments is contingent on future sales activities by our licensees. As a result, we recognize royalty revenue when reported by our licensees and when collection is reasonably assured.

Revenue from government and private agency grants are recognized as the related research expenses are incurred and to the extent that funding is approved. Additionally, we recognize revenue based on the facilities and administrative cost rate reimbursable per the terms of the grant awards.

Research and Development Expenses and Accruals

Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.

We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, completion of portions of the clinical trial or similar conditions. Our accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties.

Stock-Based Compensation

Stock-based compensation expense for stock options and other stock awards is estimated at the grant date based on the award’s fair value-based measurement. The fair value-based measurement of stock options is calculated using the Black-Scholes option valuation model and is recognized on a straight-line basis over the option’s vesting period, assuming an annual forfeiture rate of 5% for our senior management group and 13% for all other employees. Determining the appropriate fair value-based measurement requires the input of highly subjective assumptions, including the expected life of the option and expected stock price volatility. The senior management group and all other employees were grouped and considered separately for valuation purposes. See Note 13, “Stockholder’s Equity” for further information on our equity incentive plans.

Income Taxes

We account for income taxes using the asset and liability method, under which deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Additionally, we assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. We have provided a full valuation allowance on our deferred tax assets at December 31, 2012 and 2011 because we believe it is more likely than not that our deferred tax assets will not be realized as of December 31, 2012, and 2011.

We have no unrecognized tax benefits as of December 31, 2012, including no accrued amounts for interest and penalties. We do not anticipate that total unrecognized tax benefits will significantly change prior to December 31, 2013. Our policy will be to recognize interest and penalties related to income taxes, if any, as a component of general and administrative expense. We are subject to income tax examinations for U.S. federal and state income taxes from 1996 forward. We are subject to tax examination in Germany from 2010 forward. See Note 15, “Income Taxes” for further information on our tax position.

Recent Accounting Pronouncements

Accounting Standards Update 2011-04

In May 2011, the FASB issued ASU No. 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS. This ASU is the result of joint efforts by the FASB and International Accounting Standards Board to develop a single, converged fair value framework. While this ASU is largely consistent with existing fair value measurement principles in GAAP, it expands Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement existing disclosure requirements for fair value measurements and makes other amendments. Many of these amendments were made to eliminate unnecessary wording differences between GAAP and International Financial Reporting Standards, which could change how fair value measurement guidance in ASC 820 is applied. We adopted the disclosure requirements in 2012 and included the required disclosure in Note 3 “Fair Value Measurements.”

Accounting Standards Update 2011-05

In June 2011, the FASB issued ASU No. 2011-05, Presentation of Comprehensive Income. This ASU gives an entity the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. We adopted this presentation of comprehensive income in 2012.

Accounting Standards Update 2011-08

In September 2011, the FASB issued ASU No. 2011-08, Testing Goodwill for Impairment. This ASU allows an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under this ASU, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. This ASU includes a number of events and circumstances for an entity to consider in conducting the qualitative assessment. ASU No. 2011-08 was effective for us in 2012. The adoption of this ASU did not have a material impact on the Company’s financial position or results of operations.

Fair Value Measurements

12 Months Ended

Dec. 31, 2012

Fair Value Measurements

3. Fair Value Measurements

The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

•

Level 1—Quoted prices in active markets for identical assets or liabilities;

•

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Recurring Fair Value Measurements

The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis as of December 31, 2012 and 2011 (in thousands):


	Level 1		Level 2		Level 3		Total
December 31, 2012
Money market funds	$	3,140	$	—	$	—	$	3,140
U.S. government agency securities		—		119,233		—		119,233
U.S. treasury securities		—		500		—		500
Municipal securities		—		715		—		715

Total	$	3,140	$	120,448	$	—	$	123,588

	Level 1		Level 2		Level 3		Total
December 31, 2011
Money market funds	$	17,171	$	—	$	—	$	17,171
U.S. government agency securities		—		28,495		—		28,495
U.S. treasury securities		—		7,425		—		7,425
Corporate debt securities, secured by the U.S. government		—		58,580		—		58,580

Total	$	17,171	$	94,500	$	—	$	111,671

Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.

U.S. Government agency securities, U.S. treasury securities, municipal securities and corporate debt securities are measured at fair value using Level 2 inputs. We review trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.

We are obligated to make future contingent cash payments to the former Holdings shareholders related to certain payments received by us, if any, from future partnering agreements pertaining to our hepatitis C and cancer therapy programs. We estimated the valuation of this contingent liability using a discounted cash flow model. The discounted cash flow model was derived from management’s assumptions regarding the timing, amounts, and probability of potential upfront and milestone payments for the development and/or commercialization of the hepatitis C program based on transactions for similar stage programs by other companies. These cash flows were discounted at a rate of 16% for the fiscal year ended December 31, 2010.

Changes in the fair value of the contingent consideration liability are recognized in “other income (expense)” in the consolidated statements of operations in the period of the change. During the fiscal year ended December 31, 2010, we reduced the assumed probability of our receipt of upfront and milestone payments from a potential partnership and extended the timing of when these expected receipts would occur. In addition, based on our assumptions regarding our beta and risk free interest rate used in the discounted cash flow model, the change in fair value of the contingent consideration liability resulted in other income of $2.2 million for the fiscal year ended December 31, 2010. During the year ended December 31, 2011, we determined that we would not receive any upfront or milestone payments from a potential partnership for our hepatitis C therapy program and, therefore, estimated the fair value of the liability to be zero as of December 31, 2011 resulting in other income of $0.8 million. There was no change in this determination during 2012. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement.

The following table represents the changes in the fair value measurement of the contingent liability (in thousands):


Contingent liability to Holdings	Amount
Acquisition date fair value measurement at December 30, 2009	$	3,040
Adjustment to fair value measurement		(2,197	)

Balance as of December 31, 2010		843
Adjustment to fair value measurement		(843	)

Balance as of December 31, 2011 and 2012	$	—

In connection with our purchase of all of the outstanding equity of Symphony Dynamo, Inc. (“SDI”) on December 30, 2009, we issued warrants to Holdings that were subject to certain anti-dilution protection in the event that we issued other equity securities within six months from December 30, 2009. Due to this adjustment provision, the warrants did not meet the criteria set forth in ASC 815, Derivatives and Hedging, to be considered indexed to our own stock and therefore were recorded as a liability at fair value, which was estimated at the issuance date using the Black-Scholes Model. This fair value measurement was based on significant inputs not observed in the market and thus represented a Level 3 measurement. In connection with an equity offering completed in April 2010 prior to the expiration of the anti-dilution provision, Holdings received warrants to purchase 7,038,210 shares of common stock (“April 2010 Warrants”). The warrants issued on December 30, 2009 were cancelled upon the issuance of the April 2010 Warrants.

The incremental fair value of the April 2010 Warrants was remeasured at June 30, 2010, and resulted in an increase of $9.5 million to the warrant liability, which was reported as other expense in the consolidated statement of operations. Following the expiration of Symphony’s anti-dilution protection on June 30, 2010, the value of the April 2010 Warrants of $12 million was reclassified into stockholders’ equity in the consolidated balance sheet.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Cash, Cash Equivalents and Marketable Securities

12 Months Ended

Dec. 31, 2012

Cash, Cash Equivalents and Marketable Securities

4. Cash, Cash Equivalents and Marketable Securities

The following is a summary of cash, cash equivalents and marketable securities as of December 31, 2012, and 2011 (in thousands):


	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2012
Cash and cash equivalents:
Cash	$	1,542	$	—	$	—		$	1,542
Money market funds		3,140		—		—			3,140
U.S. government agency securities		715		—		—			715
Municipal securities		2,202		—		—			2,202

Total cash and cash equivalents		7,599		—		—			7,599

Marketable securities available-for-sale:
U.S. government agency securities		116,986		46		(1	)		117,031
U.S. treasury securities		500		—		—			500

Total marketable securities available-for-sale		117,486		46		(1	)		117,531

Total cash, cash equivalents and marketable securities	$	125,085	$	46	$	(1	)	$	125,130

December 31, 2011
Cash and cash equivalents:
Cash	$	2,290	$	—	$	—		$	2,290
Money market funds		17,171		—		—			17,171
U.S. government agency securities		2,013		—		—			2,013
U.S. treasury securities		7,425		—		—			7,425
Corporate debt securities, secured by the U.S. government		3,044		—		(2	)		3,042

Total cash and cash equivalents		31,943		—		(2	)		31,941

Marketable securities available-for-sale:
U.S. government agency securities		26,488		—		(5	)		26,483
Corporate debt securities, secured by the U.S. government		55,533		9		(5	)		55,537

Total marketable securities available-for-sale		82,021		9		(10	)		82,020

Total cash, cash equivalents and marketable securities	$	113,964	$	9	$	(12	)	$	113,961

The maturities of our marketable securities available-for-sale are as follows (in thousands)


	December 31, 2012
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	79,743	$	79,772
Mature after one year through two years		37,743		37,759

	$	117,486	$	117,531

We invest in short-term money market funds, U.S. government agency securities, U.S treasury securities, municipal securities and corporate obligations secured by the Federal Deposit Insurance Corporation through the Temporary Liquidity Guarantee Program.

There were no realized gains or losses from the sale of marketable securities in the years ended December 31, 2012, 2011 and 2010. All of our investments are classified as short-term and available-for-sale, as we may not hold our investments until maturity.

Property and Equipment

12 Months Ended

Dec. 31, 2012

Property and Equipment

5. Property and Equipment

Property and equipment as of December 31, 2012, and 2011 consist of the following (in thousands):


	Estimated Useful	December 31,
	Life (In years)	2012			2011
Manufacturing equipment	5-14	$	7,574		$	7,305
Lab equipment	5-13		6,755		$	6,430
Computer equipment	3		1,807			1,488
Furniture and fixtures	3		983			978
Leasehold improvements	5-7		5,445			3,989
Assets in progress			1,047			389

			23,611			20,579
Less accumulated depreciation and amortization			(15,646	)		(14,416	)

Total		$	7,965		$	6,163

Depreciation and amortization expense on property and equipment was $1.2 million, $1.3 million and $1.4 million for the years ended December 31, 2012, 2011 and 2010, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Intangible Assets

12 Months Ended

Dec. 31, 2012

Intangible Assets

6. Intangible Assets

Intangible assets consisted primarily of manufacturing process and customer relationships related to our 2006 acquisition of Rhein. The manufacturing process derives from the methods for making proteins in Hansenula yeast, which is a process we use to make a key component in the production of hepatitis B vaccine. The customer relationships derive from Rhein’s ability to sell existing, in-process and future products to its existing customers. Purchased intangible assets other than goodwill are amortized on a straight-line basis over their respective useful lives. The manufacturing process and customer relationships were amortized over their estimated useful lives of five years. Both the manufacturing process and customer relationships intangible assets were fully amortized as of the years ended December 31, 2012, and 2011. Amortization of intangible assets was $0.3 million and $1.0 million for the years ended December 31, 2011, and 2010, respectively.

Current Accrued Liabilities

12 Months Ended

Dec. 31, 2012

Current Accrued Liabilities

7. Current Accrued Liabilities

Current accrued liabilities as of December 31, 2012, and 2011 consist of the following (in thousands):


	December 31,
	2012		2011
Payroll and related expenses	$	4,538	$	3,224
Legal expenses		396		220
Third party research and development expenses		3,207		3,903
Other accrued liabilities		1,922		812

Total	$	10,063	$	8,159

Symphony Dynamo, Inc.

12 Months Ended

Dec. 31, 2012

Symphony Dynamo, Inc.

8. Symphony Dynamo, Inc.

On April 18, 2006, we, Symphony and Holdings entered into a transaction involving a series of related agreements providing for the advancement of certain of our immunostimulatory sequences-based programs for cancer, hepatitis B and hepatitis C therapy (collectively, the “Programs”). Pursuant to these agreements, Symphony formed SDI and invested $50 million to fund the Programs, and we licensed to Holdings our intellectual property rights related to the Programs, which were assigned to SDI. As a result of these agreements, Symphony owned 100% of the equity of Holdings, which owned 100% of the equity of SDI.

In connection with the transaction described above, Holdings granted to us an exclusive purchase option that gave us the right, but not the obligation, to acquire the outstanding equity securities of SDI, which would result in our reacquisition of the intellectual property rights that we licensed to Holdings (the “Original Purchase Option”). In exchange for the Original Purchase Option, we granted Holdings five-year warrants to purchase up to 2,000,000 shares of our common stock at an exercise price of $7.32 per share pursuant to a warrant purchase agreement (the “Original Warrants”), and granted certain registration rights to Holdings pursuant to a registration rights agreement. We also received an exclusive option to purchase either the hepatitis B or hepatitis C therapy program (the “Program Option”) during the first year of the arrangement. In April 2007, we exercised the Program Option for the hepatitis B program which resulted in the recognition of a $15 million liability to Symphony. We remained primarily responsible for the development of the cancer and hepatitis C therapy programs in accordance with a development plan and related development budgets that we agreed to with Holdings.

Prior to the acquisition of all of the outstanding equity of SDI on December 30, 2009, we consolidated the financial position and results of operations of SDI. In November 2009, we entered into an agreement with Holdings to modify the provisions of and to exercise the Original Purchase Option (the “Amended Purchase Option”). We completed the acquisition of all of the outstanding equity of SDI on December 30, 2009. In exchange for all of the outstanding equity of SDI, we issued to Symphony and certain of its co-investors: (i) 13,000,000 shares of common stock (the “Shares”); (ii) 5-year warrants to purchase 2,000,000 shares of common stock with an exercise price of $1.94 per share (the “Warrants”); and (iii) a non-interest bearing note in the principal amount of $15 million, due December 31, 2012, payable in cash, our common stock or a combination thereof at our discretion, which obligation was previously payable solely in cash on April 18, 2011 (the “Note”). In addition, we agreed to contingent cash payments from us equal to 50% of the first $50 million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any third party with respect to the development and/or commercialization of the cancer and hepatitis C therapies originally licensed to SDI. The Original Warrants held by Symphony were cancelled as part of this transaction.

We recorded the acquisition of all of the outstanding equity of SDI pursuant to the Amended Purchase Option as a return of equity to the noncontrolling interest. The acquisition was accounted for as a capital transaction that did not affect our consolidated net loss. However, because the acquisition was accounted for as a capital transaction, the consideration paid in excess of the carrying value of the noncontrolling interest in SDI is treated as a deemed dividend for purposes of reporting net loss and earnings per share.

The estimated fair values of the warrants transferred were calculated using the Black-Scholes valuation model.

We estimated the fair value of the Note using a net present value model with a discount rate of 17%. Imputed interest was recorded as interest expense over the term of the loan using the interest rate method. We paid in cash the $15 million principal balance of the Note on December 31, 2012.

The Shares and Warrants were subject to certain anti-dilution protection in the event that we issued other equity securities within six months from December 30, 2009. As a result of an equity offering completed in April 2010 prior to the expiration of the anti-dilution provision, Symphony received an additional 1,076,420 shares of common stock (“April 2010 Shares”) and warrants to purchase 7,038,210 shares of common stock (“April 2010 Warrants”) having the same terms as the warrants sold in the offering, which have an exercise price of $1.50 per share and a term of five years. The Warrants issued on December 30, 2009 were cancelled upon the issuance of the April 2010 Warrants.

The fair value of the April 2010 Shares and incremental fair value of the April 2010 Warrants provided to Symphony, as measured upon issuance and remeasured at June 30, 2010, resulted in non-operating expense of $11.1 million in the second quarter of 2010. This also resulted in an increase of $9.5 million to the warrant liability and an increase of $1.6 million to additional paid in capital as of June 30, 2010. Following the expiration date of Symphony’s anti-dilution protection, on June 30, 2010, the value of the April 2010 Warrants of $12.0 million was reclassified into stockholders’ equity in the consolidated balance sheets. As of December 31, 2012, warrants to purchase 6,765,128 shares remained outstanding.

- Definition

The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.

+ References + Details

Financing Agreements

12 Months Ended

Dec. 31, 2012

Financing Agreements

9. Financing Agreements

On May 9, 2012, we completed an underwritten public offering of 17,500,000 shares of our common stock to the public at $4.25 per share. The net proceeds to us from this offering were $69.6 million, after deducting offering expenses.

On November 3, 2011, we completed an underwritten public offering of 27,600,000 shares of our common stock including 3,600,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters at a price to the public of $2.50 per share. The net proceeds to us from this offering were $64.5 million, after deducting offering expenses.

On November 2, 2010, we completed an underwritten public offering of 26,450,000 shares of our common stock including 3,450,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters at a price to the public of $1.70 per share. The net proceeds to us from this offering were $42.0 million, after deducting offering expenses.

On September 20, 2010, we entered into a Purchase Agreement with Aspire Capital, which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $30.0 million of shares of our common stock (the “Purchase Shares”) over the 25-month term of the Purchase Agreement. Under the Purchase Agreement, we agreed to pay Aspire Capital a commitment fee equal to 4% of $30 million in consideration for Aspire Capital’s obligation to purchase up to $30 million of our common stock. We paid this commitment fee of $1.2 million by the issuance of 600,000 shares of our common stock and this fee was recorded as a cost of raising capital and netted against the gross proceeds from the Purchase Agreement in September 2010. During 2010, we sold 2,350,000 shares of common stock to Aspire Capital for $3.3 million and during 2011 we sold 10,995,210 shares of common stock for $26.7 million, which totaled the proceeds available to us of $30 million under the Purchase Agreement.

On April 16, 2010, we completed an underwritten public offering resulting in net proceeds of $41.1 million, after deducting offering expenses of approximately $3.0 million, from the sale of 30,293,000 units at a per unit price of $1.4525. Each unit consisted of one share of common stock and one warrant to purchase 0.5 of a share of common stock. Each warrant has an exercise price of $1.50 per share, and is exercisable for a period of five years from the date of issuance. From this offering, warrants to purchase an aggregate of 10,913,873 shares of our common stock were outstanding as of December 31, 2012 (including the warrants to purchase 6,765,128 shares provided to Symphony as described in Note 8 “Symphony Dynamo, Inc.”).

On August 17, 2009, we entered into an equity distribution agreement with Wedbush Morgan Securities, Inc. (“Wedbush”) pursuant to which we could offer and sell shares of our common stock having an aggregate offering price of up to $15 million from time to time through Wedbush as our sales agent or to Wedbush as a principal. During the fiscal year ended December 31, 2009, we sold 1,281,100 shares of common stock under the agreement with Wedbush as our sales agent for aggregate net proceeds of $2.3 million after deducting commissions paid to Wedbush and offering expenses. On September 14, 2010, the Company terminated the agreement with Wedbush. Prior to the termination of the agreement on September 14, 2010, during the year ended December 31, 2010, we sold 900,860 shares of common stock under the agreement with Wedbush as our sales agent for net proceeds of $1.2 million.

In connection with a 2007 loan agreement that was subsequently terminated in 2008, we issued warrants to purchase up to 3,550,000 shares of our common stock as follows:


Warrant Issuance Date	Shares Issuable (in thousands)		Expiration Date		Exercise Price per Share		Outstanding as of December 31, 2012
July 18, 2007		1,250		2/26/2014	$	5.13		1,250
October 18, 2007		1,300		2/26/2014	$	1.68		250
December 27, 2007		300		2/26/2014	$	5.65		300
December 27, 2007		700		2/26/2014	$	1.68		—

Total		3,550						1,800

As December 31, 2012, warrants to purchase an aggregate of approximately 12,700,000 shares of our common stock were outstanding.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2012

Commitments and Contingencies

10. Commitments and Contingencies

We lease our facilities in Berkeley, California (the “Berkeley Lease”), and Düsseldorf, Germany (the “Düsseldorf Lease”), under operating leases that expire in June 2018 and March 2023, respectively. Total net rent expense related to our operating leases for the years ended December 31, 2012, 2011 and 2010, was $1.7 million, $1.7 million and $2.6 million, respectively. Deferred rent was $0.6 million as of both December 31, 2012 and 2011.

Future minimum payments under the non-cancelable portion of our operating leases at December 31, 2012, excluding payments from sublease agreements of $41 thousand, are as follows (in thousands):


Years ending December 31,
2013	$	2,064
2014		2,210
2015		2,260
2016		2,311
2017		2,360
Thereafter		3,727

Total	$	14,932

During the fourth quarter of 2004, we established a letter of credit with Silicon Valley Bank as security for our Berkeley Lease in the amount of $0.4 million. The letter of credit remained outstanding as of December 31, 2012, and is collateralized by a certificate of deposit which has been included in restricted cash in the consolidated balance sheets as of December 31, 2012 and 2011. Under the terms of the Berkeley Lease, if the total amount of our cash, cash equivalents and marketable securities falls below $20 million for a period of more than 30 consecutive days during the lease term, the amount of the required security deposit will increase to $1.1 million, until such time as our projected cash and cash equivalents will exceed $20 million for the remainder of the lease term, or until our actual cash and cash equivalents remains above $20 million for a period of 12 consecutive months.

We established a letter of credit with Deutsche Bank as security for our Düsseldorf Lease in the amount of approximately 0.2 million Euros. The letter of credit remained outstanding as of December 31, 2012 and is collateralized by a certificate of deposit which has been included in restricted cash in the consolidated balance sheets as of December 31, 2012, and 2011.

In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies. We consider these potential obligations to be contingent and have summarized all significant arrangements below.

We rely on research institutions, contract research organizations, clinical investigators, material manufacturers and other consultants. As of December 31, 2012, under the terms of our agreements, we are obligated to make future payments as services are provided of approximately $9.9 million through 2015. These agreements are terminable by us upon written notice. We are generally only liable for actual effort expended by the organizations at any point in time during the contract, subject to certain termination fees and penalties.

Under the terms of our exclusive license agreements with the Regents of the University of California, as amended, for certain technology and related patent rights and materials, we pay annual license or maintenance fees and will be required to pay milestones and royalties on net sales of products originating from the licensed technologies, if any.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Collaborative Research, Development and License Agreements

12 Months Ended

Dec. 31, 2012

Collaborative Research, Development and License Agreements

11. Collaborative Research, Development and License Agreements

GlaxoSmithKline

In December 2008, we entered into a worldwide strategic alliance with GSK to discover, develop and commercialize toll-like receptor (“TLR”) inhibitors. We received an initial payment of $10 million and agreed to conduct research and early clinical development in up to four programs. The deliverables under this arrangement did not have stand-alone value and so did not qualify as separate units of accounting. In 2011, we earned $15 million in milestone payments related to the initiation of Phase 1 and proof-of-mechanism clinical trials of DV1179 in systemic lupus erythematosus patients and expansion of our collaboration with GSK to develop a TLR8 inhibitor. We are eligible to receive future development milestone payments which we have determined to be substantive milestones. GSK can exercise its exclusive option to license each program upon achievement of certain events and we are eligible to receive contingent option exercise payments. If GSK exercises an option, GSK would carry out further development and commercialization of the corresponding products. We are eligible to receive tiered, up to double-digit royalties on sales of any products originating from the collaboration and have retained an option to co-develop and co-promote one product under this agreement.

Revenue from the initial payment from GSK was deferred and is being recognized over the expected period of performance under the agreement which is estimated to be seven years. The following table summarizes the revenues earned under our agreement with GSK (in thousands):


	Years ended December 31,
	2012		2011		2010
Initial payment	$	1,428	$	1,428	$	1,428
Milestone revenue		—		15,000		—

Total	$	1,428	$	16,428	$	1,428

As of December 31, 2012 and 2011, deferred revenue relating to the initial payment was $4.2 million and $5.7 million, respectively.

Absent early termination, the agreement will expire when all of GSK’s payment obligations expire. Either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of the agreement. Either party may terminate the agreement in the event of insolvency of the other party. GSK also has the option to terminate the agreement without cause upon prior written notice within a specified window of time dependent upon the stage of clinical development of the programs.

AstraZeneca

In September 2006, we entered into a three-year research collaboration and license agreement with AstraZeneca for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The deliverables under this arrangement did not have stand-alone value and so did not qualify as separate units of accounting. We received an upfront payment of $10 million. In 2008, we received a milestone payment of $4.5 million for the nomination of the first candidate drug, AZD1419, for asthma. The research term of this agreement was extended through July 2010.

In October 2011, we amended our agreement with AstraZeneca to provide that we will conduct initial clinical development of AZD1419. Under the terms of the amended agreement, AstraZeneca will fund all program expenses to cover the cost of development activities through Phase 2a, estimated to total approximately $20 million. We received an initial payment of $3 million to begin the clinical development program. In the first quarter of 2012, we received a $2.6 million payment to advance AZD1419 into preclinical toxicology studies and these toxicology studies were completed in the third quarter of 2012. We and AstraZeneca have agreed to advance AZD1419 towards a Phase 1 clinical trial, which resulted in a development funding payment of $6 million, received in the fourth quarter of 2012. If AstraZeneca chooses to advance the program following completion of Phase 2a, we will receive a $20 million milestone payment and AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma product. Additionally, we are eligible to receive potential future development funding payments and, upon commercialization, we are eligible to receive royalties based on product sales of any products originating from the collaboration. We have the option to co-promote in the United States products arising from the collaboration, if any. AstraZeneca has the right to sublicense its rights upon our prior consent.

Revenue from the 2011 amendment has been deferred and is being recognized as the development work is performed over the estimated performance period of approximately 50 months. The following table summarizes the revenues earned under our agreement with AstraZeneca (in thousands):


	Years ended December 31,
	2012		2011		2010
Initial payments	$	720	$	120	$	10,778
Performance of research activities		2,462		642		3,315

Total	$	3,182	$	762	$	14,093

As of December 31, 2012, and December 31, 2011, deferred revenue from the initial payment and development funding payments was $7.7 million and $4.9 million, respectively.

Absent early termination, the agreement will expire when all of AstraZeneca’s payment obligations expire. AstraZeneca has the right to terminate the agreement at any time upon prior written notice and either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of the agreement.

National Institutes of Health (“NIH”) and Other Funding

We have been awarded various grants from the NIH and the NIH’s National Institute of Allergy and Infectious Disease (“NIAID”) in order to fund research. The awards are related to specific research objectives and we earn revenue as the related research expenses are incurred. We have earned revenue during the three years ended December 31, 2012, 2011 and 2010 from the following awards:

•

June 2012, NIH awarded us $0.6 million to fund research in screening for inhibitors of TLR8 for treatment of autoimmune diseases.

•

May 2012, NIH awarded us $0.4 million to fund development of TLR8 inhibitors for treatment of rheumatoid arthritis.

•

July 2011, NIH awarded us $0.6 million to fund research in preclinical models of skin autoimmune inflammation.

•

August 2010, NIAID awarded us a grant from the NIH’s National Institute of Allergy and Infectious Disease (“NIAID”) to take a systems biology approach to study the differences between individuals who do or do not respond to vaccination against the hepatitis B virus. This study will be one of several projects conducted under a grant to the Baylor Institute of Immunology Research in Dallas as part of the Human Immune Phenotyping Centers program. We have been awarded a total of $1.1 million under this grant.

•

July 2010, NIH awarded us $0.6 million to explore the feasibility of developing a universal vaccine to prevent infection by human papilloma virus.

•

September 2008, NIAID awarded us a five-year $17 million contract to develop our ISS technology using TLR9 agonists as vaccine adjuvants. The contract supports adjuvant development for anthrax as well as other disease models.

•

July 2008, NIH awarded us a $1.8 million to develop a therapy for systemic lupus erythematosus, an autoimmune disease.

The following table summarizes the revenues earned under the various arrangements with the NIH and NIAID (in thousands):


	Years ended December 31,
	2012		2011		2010
NIAID contracts	$	3,571	$	2,730	$	3,197
All other NIH contracts		368		380		743

Total grant revenue	$	3,939	$	3,110	$	3,940

Merck & Co., Inc. (“Merck”)

In October 2007, we entered into a global license and development collaboration agreement and a related manufacturing agreement with Merck to jointly develop HEPLISAV. On December 18, 2008, Merck provided notice of its termination of the collaboration, at which time all development, manufacturing and commercialization rights to HEPLISAV reverted to us. In March 2010, we recognized collaboration revenue of $4 million upon receipt of a payment to us in satisfaction of Merck’s obligations for the wind down period following Merck’s written notice of termination.

Net Loss Per Share

12 Months Ended

Dec. 31, 2012

Net Loss Per Share

12. Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to us by the weighted-average number of common shares outstanding during the period and dilutive potential common shares using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by us, options and warrants are considered to be dilutive potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive.


	December 31,
	2012			2011			2010
Basic and diluted net loss per share (in thousands, except per share amounts):
Numerator:
Net loss	$	(69,949	)	$	(48,597	)	$	(57,308	)

Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding		170,469			125,101			82,463

Basic and diluted net loss per share	$	(0.41	)	$	(0.39	)	$	(0.69	)

Outstanding warrants, stock options and stock subject to repurchase by us under stock awards were excluded from the calculation of net loss per share as the effect of their inclusion would have been anti-dilutive.


	December 31,
	2012		2011		2010
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Stock options and stock awards		15,561		11,101		7,288
Warrants		12,714		25,729		25,734

		28,275		36,830		33,022

Stockholders' Equity

12 Months Ended

Dec. 31, 2012

Stockholders' Equity

13. Stockholders’ Equity

Stock Plans

As of December 31, 2012, we had four share-based compensation plans.

1997 Equity Incentive Plan (“1997 Plan”)

The 1997 Plan was adopted on January 22, 1997 and provided for the issuance of up to 3,443,630 shares of our common stock to employees and non-employees of the Company. Options granted under the 1997 Plan were either incentive stock options or nonqualified stock options. Options under the 1997 Plan were granted for periods of up to ten years and at prices no less than 85% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors, provided, however, that (i) the exercise price of the incentive stock options shall not be less than 100% of the estimated fair value of the shares on the date of grant and (ii) the exercise price of the incentive stock options granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The options were exercisable immediately and generally vested over a four-year period for stock options issued to employees, directors and scientific advisors and vested quarterly over a four-year period or immediately for stock options issued to all other non-employees. All unvested shares issued under the 1997 Plan are subject to repurchase rights by the Company under such conditions as agreed to by the Company and the optionee. The 1997 Plan expired in the first quarter of 2007. Upon expiration of the 1997 Plan, 273,188 shares previously available for grant expired. Any outstanding options under the 1997 Plan that are cancelled in future periods will automatically expire and will no longer be available for grant. As of December 31, 2012, options to purchase 471,788 shares of common stock remained outstanding under the 1997 Plan.

2004 Stock Incentive Plan (“2004 Plan”)

The 2004 Plan was adopted in January 2004 by the Board of Directors and stockholders and became effective on February 11, 2004. This plan provided for the issuance of up to 3,500,000 shares of our common stock plus an annual increase. Subsequently, we discontinued granting stock options under the 1997 Plan. Options under the 2004 Plan were granted for periods of up to ten years and the exercise price of all incentive stock options granted under the 2004 Plan was at least equal to 100% of the fair market value of the common stock on the date of grant. If, however, incentive stock options were granted to an employee who owns stock possessing more than 10% of the voting power of all classes of the Company’s stock or the stock of any parent or subsidiary of the Company, the exercise price of any incentive stock option granted must equal at least 110% of the fair market value on the grant date and the maximum term of these incentive stock options must not exceed five years. The maximum term of an incentive stock option granted to any other participant must not exceed ten years. The 2004 Plan authorizes the issuance of various forms of stock-based awards including stock options, restricted stock, restricted stock units and other equity awards to employees, consultants and members of the board of directors. As of December 31, 2012, options to purchase 4,298,027 shares of common stock remained outstanding under the 2004 Plan.

2010 Employment Inducement Award Plan (“Inducement Plan”)

The Inducement Plan was adopted in January 2010 by our Board of Directors to induce qualified individuals to join Dynavax. This Inducement Plan provided for the issuance of up to 1,500,000 shares of our common stock and became effective on January 8, 2010. Stockholder approval of the Inducement Plan is not required under NASDAQ Marketplace Rule 5635(c)(4). As of December 31, 2012, options to purchase 779,000 shares of common stock remained outstanding under the Inducement Plan.

2011 Equity Incentive Plan (“2011 Plan”)

The 2011 Plan was approved by the Company’s stockholders and adopted in January 2011. The 2011 Plan provides for the issuance of up to 15,000,000 shares of our common stock to employees and non-employees of the Company and became effective on January 6, 2011. The 2011 Plan is administered by our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the 2011 Plan have a term of 10 years unless earlier terminated by the Board of Directors. Under the 2011 Plan, no additional awards will be granted under either the 2004 Plan or the Inducement Plan. As of January 6, 2011, all shares subject to awards outstanding under the 2004 Plan and Inducement Plan that expire or are forfeited will be included in the reserve for the 2011 Plan to the extent such shares would otherwise return to such plans. As of December 31, 2012, options to purchase 8,257,406 shares of common stock remained outstanding under the 2011 Plan.

Activity under our stock plans is set forth below:


	Shares Underlying Outstanding Options (in thousands)			Weighted-Average Exercise Price Per Share (in thousands)		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2011		10,987		$	3.10
Options granted		4,534			3.68
Options exercised		(1,166	)		1.79
Options cancelled:
Options forfeited (unvested)		(505	)		3.32
Options cancelled (vested)		(44	)		5.53

Balance at December 31, 2012		13,806		$	3.38		7.26	$	4,015

Vested and expected to vest at December 31, 2012		12,886		$	3.37		7.13	$	3,955

Exercisable at December 31, 2012		7,226		$	3.49		5.91	$	2,825

The total intrinsic value of stock options exercised during the years ended December 31, 2012, 2011 and 2010 was, $2.7 million, $0.1 million and $0.1 million, respectively. The total intrinsic value of exercised stock options is calculated based on the difference between the exercise price and the quoted market price of our common stock as of the close of the exercise date.

The total fair value of stock options vested during the years ended December 31, 2012, 2011 and 2010 was, $9.6 million, $2.8 million and $4.1 million, respectively.

Our non-vested stock awards are comprised of restricted stock units granted with performance-based vesting criteria. A summary of the status of non-vested restricted stock units as of December 31, 2012, and activities during 2012 is summarized as follows:


	Number of Shares (In thousands)			Weighted-Average Grant-Date Fair Value
Non-vested as of December 31, 2011		115		$	1.98
Granted		1,815		$	4.23
Vested		(115	)	$	1.98
Forfeited or expired		(60	)	$	4.22

Non-vested as of December 31, 2012		1,755		$	4.23

Stock-based compensation expense related to restricted stock units was approximately $0.2 million for the year ended December 31, 2012. The aggregate intrinsic value of the restricted stock units outstanding as of December 31, 2012, based on our stock price on that date, was $5.0 million.

The weighted average grant-date fair value of restricted stock units granted during the years ended December 31, 2012 and 2010 was, $4.23 and $1.98, respectively. No restricted stock units were granted during 2011. The total fair value of restricted stock units vested during the years ended December 31, 2012 and 2011 was, $0.2 million and $0.8 million, respectively. No restricted stock units vested during 2010.

Employee Stock Purchase Plan

In January 2004, the Board of Directors and stockholders adopted the 2004 Employee Stock Purchase Plan (the “Purchase Plan”). The Purchase Plan provides for the purchase of common stock by eligible employees and became effective on February 11, 2004. The purchase price per share is the lesser of (i) 85% of the fair market value of the common stock on the commencement of the offer period (generally, the fifteenth day in February or August) or (ii) 85% of the fair market value of the common stock on the exercise date, which is the last day of a purchase period (generally, the fourteenth day in February or August).

As of December 31, 2012, 996,000 shares were reserved and approved for issuance under the Purchase Plan, subject to adjustment for a stock split, or any future stock dividend or other similar change in our common stock or capital structure. To date, employees have acquired 698,724 shares of our common stock under the Purchase Plan. As of December 31, 2012, 297,276 shares of our common stock remained available for future purchases.

Stock-Based Compensation

Under our stock-based compensation plans, option awards generally vest over a four-year period contingent upon continuous service and expire ten years from the date of grant (or earlier upon termination of continuous service). The Company has also granted performance-based equity awards to certain of our employees under the 2011 Plan, the 2004 Plan and the Inducement Plan. As of December 31, 2012, 2,617,966 shares were outstanding related to options and restricted stock units subject to these performance-based vesting criteria. The fair value of each option is estimated on the date of grant using the Black-Scholes option valuation model and the following weighted-average assumptions:


	Stock Options									Employee Stock Purchase Plan
	Years Ended December 31,									Years Ended December 31,
	2012			2011			2010			2012			2011			2010
Weighted-average fair value	$	3.30		$	2.76		$	1.49		$	3.53		$	2.09		$	1.47
Risk-free interest rate		0.5	%		1.3	%		1.7	%		0.2	%		0.3	%		0.4	%
Expected life (in years)		4.2			4.0			4.0			1.1			1.2			0.9
Volatility		1.6			1.6			1.6			1.6			1.6			1.6

Expected volatility is based on historical volatility of our stock price. The expected life of options granted is estimated based on historical option exercise and employee termination data, while giving consideration to options that have not yet completed a full life cycle. Our senior management, who hold a majority of the options outstanding, and other employees were grouped and considered separately for valuation purposes. The expected life of the options for senior management is six years and for other employees five and a half years. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is zero percent for all years and is based on our history and expectation of dividend payouts.

Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods. For equity awards with performance-based vesting criteria, the fair value is amortized to expense when the achievement of the vesting criteria becomes probable.

We recognized the following amounts of stock-based compensation expense (in thousands):


	Years Ended December 31,
	2012		2011		2010
Employees and directors stock-based compensation expense	$	10,439	$	5,185	$	2,378
Non-employees stock-based compensation expense		—		4		32

Total	$	10,439	$	5,189	$	2,410


	Years Ended December 31,
	2012		2011		2010
Research and development	$	3,514	$	2,103	$	632
General and administrative		6,925		3,086		1,778

Total	$	10,439	$	5,189	$	2,410

In the fourth quarter of 2012, we recognized $1.5 million in additional stock-based compensation expense due to a modification of the terms of stock options related to an amended management continuity and severance agreement with one of our executive officers.

As of December 31, 2012, the total unrecognized compensation cost related to non-vested stock options deemed probable of vesting, including all stock options with time-based vesting, net of estimated forfeitures, amounted to $14.3 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.3 years. As of December 31, 2012, the total unrecognized compensation cost related to non-vested stock options not deemed probable of vesting, net of estimated forfeitures, amounted to $0.3 million.

As of December 31, 2012, the total unrecognized compensation cost related to non-vested equity awards not deemed probable of vesting, net of estimated forfeitures, amounted to $6.3 million.

As of December 31, 2012, the total unrecognized compensation cost related to shares of our common stock under the Purchase Plan, amounted to $0.3 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.0 years.

Warrants

As December 31, 2012, warrants to purchase an aggregate of approximately 12,700,000 shares of our common stock were outstanding. The warrants are exercisable at $1.50 to $5.65 per share. During the years ended December 31, 2012, and 2011, warrants were exercised to purchase an aggregate of approximately 13,000,000 and 4,500,000 shares, respectively, of our common stock.

Preferred Stock Rights

On November 4, 2008, our Board of Directors declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of our Common Stock, par value $0.001 per share (the “Common Shares”). The dividend was payable on November 17, 2008 to the stockholders of record on that date. Each Right entitles the registered holder to purchase from us one one-hundredth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share (the “Preferred Shares”), at a price of $6.00 per one one-hundredth of a Preferred Share, subject to adjustment. Upon the acquisition of, or announcement of the intent to acquire, 20 percent or more of our outstanding Common Shares by a person, entity or group of affiliated or associated persons (“Acquiring Person”), each holder of a Right, other than Rights held by the Acquiring Person, will have the right to purchase that number of Common Shares having a market value of two times the exercise price of the Right. If we are acquired in a merger or other business combination transaction or 50 percent or more of our assets or earning power are sold to an Acquiring Person, each holder of a Right will thereafter have the right to purchase, at the then current exercise price of the Right, that number of shares of common stock of the acquiring company which at the time of such transaction will have a market value of two times the exercise price of the Right. The Rights plan is intended to maximize the value of the Company in the event of an unsolicited attempt to take over the Company in a manner or on terms not approved by the Company’s Board of Directors. The Rights will expire on November 17, 2018, unless the Rights are earlier redeemed or exchanged by the Company.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2012
Employee Benefit Plan	14. Employee Benefit Plan We maintain a 401(k) Plan, which qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Under the 401(k) Plan, participating employees may defer a portion of their pretax earnings. We may, at our discretion, contribute for the benefit of eligible employees. To date, we have not contributed to the 401(k) Plan.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2012

Income Taxes

15. Income Taxes

Consolidated income (loss) before provision for income taxes consisted of the following (in thousands):


	Years Ended December 31,
	2012			2011			2010
U.S.	$	(70,792	)	$	(49,990	)	$	(56,379	)
Non U.S.		843			1,393			(929	)

Total	$	(69,949	)	$	(48,597	)	$	(57,308	)

No income tax expense was recorded for the years ended December 31, 2012, 2011 and 2010 due to net operating loss carryforwards to offset the net income at Dynavax Europe and a valuation allowance which offsets the deferred tax assets. The difference between the consolidated income tax benefit and the amount computed by applying the federal statutory income tax rate to the consolidated loss before income taxes was as follows (in thousands):


	Years Ended December 31,
	2012			2011			2010
Income tax benefit at federal statutory rate	$	(23,650	)	$	(16,523	)	$	(19,486	)
State tax		(89	)		(2,586	)		(1,617	)
Tax credits		—			(1,394	)		(2,172	)
Deferred compensation charges		1,002			595			318
Change in valuation allowance		21,966			18,099			19,863
Change in foreign tax rates		—			(34	)		22
Change in the fair value measurements		—			286			2,997
Non-deductible debt discount		—			509			420
Deemed dividend		—			273			—
Other		771			775			(345	)

Total income tax expense	$	—		$	—		$	—

Deferred tax assets and liabilities as of December 31, 2012 and 2011 consisted of the following (in thousands):


	December 31,
	2012			2011
Deferred tax assets:
Net operating loss carry forwards	$	127,529		$	103,119
Research tax credit carry forwards		18,163			17,477
Accruals and reserves		8,529			6,818
Capitalized research costs		12,757			17,278
Deferred revenue		2,180			2,189
Other		1,221			1,455

		170,379			148,336
Less valuation allowance		(170,232	)		(148,266	)

Total deferred tax assets		147			70

Deferred tax liabilities:
Acquired intangible assets		(86	)		(27	)
Other		(61	)		(43	)

Total deferred tax liabilities		(147	)		(70	)

Net deferred tax assets	$	—		$	—

The tax benefit of net operating losses, temporary differences and credit carryforwards is required to be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $22.0 million, $18.1 million and $19.9 million during the years ended December 31, 2012, 2011 and 2010, respectively. The amount of the valuation allowance for deferred tax assets associated with excess tax deductions from stock based compensation arrangements that will be allocated to contributed capital if the future tax benefits are subsequently recognized is $0.4 million.

We have not recorded deferred income taxes applicable to undistributed earnings of a foreign subsidiary that are indefinitely reinvested in foreign operations. Generally, such earnings become subject to U.S. tax upon the remittance of dividends and under certain other circumstances. It is not practicable to estimate the amount of the deferred tax liability on such undistributed earnings.

As of December 31, 2012, we had federal net operating loss carryforwards of approximately $323.8 million, which will expire in the years 2018 through 2032 and federal research and development tax credits of approximately $11.2 million, which expire in the years 2018 through 2032.

As of December 31, 2012, we had net operating loss carryforwards for California state income tax purposes of approximately $226.2 million, which expire in the years 2013 through 2032, and California state research and development tax credits of approximately $10.5 million which do not expire.

As of December 31, 2012, we had net operating loss carryforwards for foreign income tax purposes of approximately $28.0 million, which do not expire.

The Tax Reform Act of 1986 limits the annual use of net operating loss and tax credit carryforwards in certain situations where changes occur in stock ownership of a company. In the event the Company has a change in ownership, as defined, the annual utilization of such carryforwards could be limited. Due to past equity issuances and changes in ownership of Dynavax common stock, we believe that our ability to use some of our net operating losses and tax credits in the future may be limited. We are conducting an analysis under Sections 382 and 383 of the Internal Revenue Code as enacted by the Tax Reform Act of 1986, and if necessary, we will reduce our net operating losses and tax credits by any applicable limitation when our analysis is complete.

In November 2010, we received a one-time $0.7 million payment under The Patient Protection and Affordable Care Act of 2010 covering research and development costs from 2009 and 2010 for three of our qualified therapeutic discovery projects including HEPLISAV. The funds received as a result of this award were recorded as other income in the year ended December 31, 2010.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

Selected Quarterly Financial Data

12 Months Ended

Dec. 31, 2012

Selected Quarterly Financial Data

16. Selected Quarterly Financial Data (Unaudited; in thousands, except per share amounts)


	Year Ended December 31, 2012
	Q1			Q2			Q3			Q4
Revenues	$	2,350		$	2,684		$	2,874		$	1,806
Net loss	$	(16,505	)	$	(15,110	)	$	(17,791	)	$	(20,543	)
Basic and diluted net loss per share	$	(0.11	)	$	(0.09	)	$	(0.10	)	$	(0.11	)
Shares used to compute basic and diluted net loss per share		155,431			167,697			177,870			180,685


	Year Ended December 31, 2011
	Q1			Q2			Q3			Q4
Revenues	$	1,744		$	7,269		$	1,174		$	11,427
Net loss	$	(18,466	)	$	(10,635	)	$	(15,229	)	$	(4,267	)
Basic and diluted net loss per share	$	(0.16	)	$	(0.09	)	$	(0.12	)	$	(0.03	)
Shares used to compute basic and diluted net loss per share		115,726			117,864			124,069			142,482

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2012

Basis of Presentation

Basis of Presentation

Liquidity and Financial Condition

Liquidity and Financial Condition

Use of Estimates

Use of Estimates

Foreign Currency

Foreign Currency

Cash, Cash Equivalents and Marketable Securities

Cash, Cash Equivalents and Marketable Securities

•

Whether the investment has been in a continuous realized loss position for over 12 months;

•

the duration to maturity of our investments;

•

our intention to hold the investments to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost bases;

•

the credit rating, financial condition and near-term prospects of the issuer; and

•

the type of investments made.

To date, there have been no declines in fair value that have been identified as other than temporary.

Concentration of Credit Risk and Other Risks and Uncertainties

Concentration of Credit Risk and Other Risks and Uncertainties

Property and Equipment

Property and Equipment

Valuation of Long-Lived Assets and Intangible Assets

Valuation of Long-Lived Assets and Intangible Assets

Goodwill

Goodwill

Revenue Recognition

Revenue Recognition

Revenues from manufacturing services are recognized upon meeting the criteria for substantial performance and acceptance by the customer.

Research and Development Expenses and Accruals

Research and Development Expenses and Accruals

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Accounting Standards Update 2011-04

Accounting Standards Update 2011-05

Accounting Standards Update 2011-08

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2012

Fair Value Hierarchy For Financial Assets And Liabilities Measured At Fair Value On Recurring Basis


	Level 1		Level 2		Level 3		Total
December 31, 2012
Money market funds	$	3,140	$	—	$	—	$	3,140
U.S. government agency securities		—		119,233		—		119,233
U.S. treasury securities		—		500		—		500
Municipal securities		—		715		—		715

Total	$	3,140	$	120,448	$	—	$	123,588

	Level 1		Level 2		Level 3		Total
December 31, 2011
Money market funds	$	17,171	$	—	$	—	$	17,171
U.S. government agency securities		—		28,495		—		28,495
U.S. treasury securities		—		7,425		—		7,425
Corporate debt securities, secured by the U.S. government		—		58,580		—		58,580

Total	$	17,171	$	94,500	$	—	$	111,671

Changes In Fair Value Measurement Of Contingent Liability

The following table represents the changes in the fair value measurement of the contingent liability (in thousands):


Contingent liability to Holdings	Amount
Acquisition date fair value measurement at December 30, 2009	$	3,040
Adjustment to fair value measurement		(2,197	)

Balance as of December 31, 2010		843
Adjustment to fair value measurement		(843	)

Balance as of December 31, 2011 and 2012	$	—

Cash, Cash Equivalents and Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2012

Summary of Cash, Cash Equivalents and Marketable Securities

The following is a summary of cash, cash equivalents and marketable securities as of December 31, 2012, and 2011 (in thousands):


	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2012
Cash and cash equivalents:
Cash	$	1,542	$	—	$	—		$	1,542
Money market funds		3,140		—		—			3,140
U.S. government agency securities		715		—		—			715
Municipal securities		2,202		—		—			2,202

Total cash and cash equivalents		7,599		—		—			7,599

Marketable securities available-for-sale:
U.S. government agency securities		116,986		46		(1	)		117,031
U.S. treasury securities		500		—		—			500

Total marketable securities available-for-sale		117,486		46		(1	)		117,531

Total cash, cash equivalents and marketable securities	$	125,085	$	46	$	(1	)	$	125,130

December 31, 2011
Cash and cash equivalents:
Cash	$	2,290	$	—	$	—		$	2,290
Money market funds		17,171		—		—			17,171
U.S. government agency securities		2,013		—		—			2,013
U.S. treasury securities		7,425		—		—			7,425
Corporate debt securities, secured by the U.S. government		3,044		—		(2	)		3,042

Total cash and cash equivalents		31,943		—		(2	)		31,941

Marketable securities available-for-sale:
U.S. government agency securities		26,488		—		(5	)		26,483
Corporate debt securities, secured by the U.S. government		55,533		9		(5	)		55,537

Total marketable securities available-for-sale		82,021		9		(10	)		82,020

Total cash, cash equivalents and marketable securities	$	113,964	$	9	$	(12	)	$	113,961

Maturities of Marketable Securities Available-for-Sale

The maturities of our marketable securities available-for-sale are as follows (in thousands)


	December 31, 2012
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	79,743	$	79,772
Mature after one year through two years		37,743		37,759

	$	117,486	$	117,531

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2012

Component of Property and Equipment

Property and equipment as of December 31, 2012, and 2011 consist of the following (in thousands):


	Estimated Useful	December 31,
	Life (In years)	2012			2011
Manufacturing equipment	5-14	$	7,574		$	7,305
Lab equipment	5-13		6,755		$	6,430
Computer equipment	3		1,807			1,488
Furniture and fixtures	3		983			978
Leasehold improvements	5-7		5,445			3,989
Assets in progress			1,047			389

			23,611			20,579
Less accumulated depreciation and amortization			(15,646	)		(14,416	)

Total		$	7,965		$	6,163

Current Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2012

Component Of Current Accrued Liabilities

Current accrued liabilities as of December 31, 2012, and 2011 consist of the following (in thousands):


	December 31,
	2012		2011
Payroll and related expenses	$	4,538	$	3,224
Legal expenses		396		220
Third party research and development expenses		3,207		3,903
Other accrued liabilities		1,922		812

Total	$	10,063	$	8,159

Financing Agreements (Tables)

12 Months Ended

Dec. 31, 2012

Warrants Issued To Purchase Common Stock

In connection with a 2007 loan agreement that was subsequently terminated in 2008, we issued warrants to purchase up to 3,550,000 shares of our common stock as follows:


Warrant Issuance Date	Shares Issuable (in thousands)		Expiration Date		Exercise Price per Share		Outstanding as of December 31, 2012
July 18, 2007		1,250		2/26/2014	$	5.13		1,250
October 18, 2007		1,300		2/26/2014	$	1.68		250
December 27, 2007		300		2/26/2014	$	5.65		300
December 27, 2007		700		2/26/2014	$	1.68		—

Total		3,550						1,800

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2012

Future Minimum Payments Under Non-Cancelable Portion of Operating Leases

Future minimum payments under the non-cancelable portion of our operating leases at December 31, 2012, excluding payments from sublease agreements of $41 thousand, are as follows (in thousands):


Years ending December 31,
2013	$	2,064
2014		2,210
2015		2,260
2016		2,311
2017		2,360
Thereafter		3,727

Total	$	14,932

Collaborative Research, Development and License Agreements (Tables)

12 Months Ended

Dec. 31, 2012

Astra Zeneca

Summary of Revenues Earned by Major Customer

The following table summarizes the revenues earned under our agreement with AstraZeneca (in thousands):


	Years ended December 31,
	2012		2011		2010
Initial payments	$	720	$	120	$	10,778
Performance of research activities		2,462		642		3,315

Total	$	3,182	$	762	$	14,093

National Institutes of Health

Summary of Revenues Earned by Major Customer

The following table summarizes the revenues earned under the various arrangements with the NIH and NIAID (in thousands):


	Years ended December 31,
	2012		2011		2010
NIAID contracts	$	3,571	$	2,730	$	3,197
All other NIH contracts		368		380		743

Total grant revenue	$	3,939	$	3,110	$	3,940

Agreement With Gsk

Summary of Revenues Earned by Major Customer

The following table summarizes the revenues earned under our agreement with GSK (in thousands):


	Years ended December 31,
	2012		2011		2010
Initial payment	$	1,428	$	1,428	$	1,428
Milestone revenue		—		15,000		—

Total	$	1,428	$	16,428	$	1,428

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2012

Computation of Basic and Diluted Earnings Per Share


	December 31,
	2012			2011			2010
Basic and diluted net loss per share (in thousands, except per share amounts):
Numerator:
Net loss	$	(69,949	)	$	(48,597	)	$	(57,308	)

Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding		170,469			125,101			82,463

Basic and diluted net loss per share	$	(0.41	)	$	(0.39	)	$	(0.69	)


	December 31,
	2012		2011		2010
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Stock options and stock awards		15,561		11,101		7,288
Warrants		12,714		25,729		25,734

		28,275		36,830		33,022

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2012

Activity under Stock-Based Compensation Plans

Activity under our stock plans is set forth below:


	Shares Underlying Outstanding Options (in thousands)			Weighted-Average Exercise Price Per Share (in thousands)		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2011		10,987		$	3.10
Options granted		4,534			3.68
Options exercised		(1,166	)		1.79
Options cancelled:
Options forfeited (unvested)		(505	)		3.32
Options cancelled (vested)		(44	)		5.53

Balance at December 31, 2012		13,806		$	3.38		7.26	$	4,015

Vested and expected to vest at December 31, 2012		12,886		$	3.37		7.13	$	3,955

Exercisable at December 31, 2012		7,226		$	3.49		5.91	$	2,825

Summary of Restricted Stock Units Activity

A summary of the status of non-vested restricted stock units as of December 31, 2012, and activities during 2012 is summarized as follows:


	Number of Shares (In thousands)			Weighted-Average Grant-Date Fair Value
Non-vested as of December 31, 2011		115		$	1.98
Granted		1,815		$	4.23
Vested		(115	)	$	1.98
Forfeited or expired		(60	)	$	4.22

Non-vested as of December 31, 2012		1,755		$	4.23

Black-Scholes Valuation Model and Weighted-Average Assumptions

The fair value of each option is estimated on the date of grant using the Black-Scholes option valuation model and the following weighted-average assumptions:


	Stock Options									Employee Stock Purchase Plan
	Years Ended December 31,									Years Ended December 31,
	2012			2011			2010			2012			2011			2010
Weighted-average fair value	$	3.30		$	2.76		$	1.49		$	3.53		$	2.09		$	1.47
Risk-free interest rate		0.5	%		1.3	%		1.7	%		0.2	%		0.3	%		0.4	%
Expected life (in years)		4.2			4.0			4.0			1.1			1.2			0.9
Volatility		1.6			1.6			1.6			1.6			1.6			1.6

Stock-Based Compensation Expense

We recognized the following amounts of stock-based compensation expense (in thousands):


	Years Ended December 31,
	2012		2011		2010
Employees and directors stock-based compensation expense	$	10,439	$	5,185	$	2,378
Non-employees stock-based compensation expense		—		4		32

Total	$	10,439	$	5,189	$	2,410


	Years Ended December 31,
	2012		2011		2010
Research and development	$	3,514	$	2,103	$	632
General and administrative		6,925		3,086		1,778

Total	$	10,439	$	5,189	$	2,410

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2012

Component of Consolidated Income (Loss) Before Provision for Income Taxes

Consolidated income (loss) before provision for income taxes consisted of the following (in thousands):


	Years Ended December 31,
	2012			2011			2010
U.S.	$	(70,792	)	$	(49,990	)	$	(56,379	)
Non U.S.		843			1,393			(929	)

Total	$	(69,949	)	$	(48,597	)	$	(57,308	)

Difference Between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate

The difference between the consolidated income tax benefit and the amount computed by applying the federal statutory income tax rate to the consolidated loss before income taxes was as follows (in thousands):


	Years Ended December 31,
	2012			2011			2010
Income tax benefit at federal statutory rate	$	(23,650	)	$	(16,523	)	$	(19,486	)
State tax		(89	)		(2,586	)		(1,617	)
Tax credits		—			(1,394	)		(2,172	)
Deferred compensation charges		1,002			595			318
Change in valuation allowance		21,966			18,099			19,863
Change in foreign tax rates		—			(34	)		22
Change in the fair value measurements		—			286			2,997
Non-deductible debt discount		—			509			420
Deemed dividend		—			273			—
Other		771			775			(345	)

Total income tax expense	$	—		$	—		$	—

Component of Deferred Tax Assets and Liabilities

Deferred tax assets and liabilities as of December 31, 2012 and 2011 consisted of the following (in thousands):


	December 31,
	2012			2011
Deferred tax assets:
Net operating loss carry forwards	$	127,529		$	103,119
Research tax credit carry forwards		18,163			17,477
Accruals and reserves		8,529			6,818
Capitalized research costs		12,757			17,278
Deferred revenue		2,180			2,189
Other		1,221			1,455

		170,379			148,336
Less valuation allowance		(170,232	)		(148,266	)

Total deferred tax assets		147			70

Deferred tax liabilities:
Acquired intangible assets		(86	)		(27	)
Other		(61	)		(43	)

Total deferred tax liabilities		(147	)		(70	)

Net deferred tax assets	$	—		$	—

Selected Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2012

Selected Quarterly Financial Data


	Year Ended December 31, 2012
	Q1			Q2			Q3			Q4
Revenues	$	2,350		$	2,684		$	2,874		$	1,806
Net loss	$	(16,505	)	$	(15,110	)	$	(17,791	)	$	(20,543	)
Basic and diluted net loss per share	$	(0.11	)	$	(0.09	)	$	(0.10	)	$	(0.11	)
Shares used to compute basic and diluted net loss per share		155,431			167,697			177,870			180,685


	Year Ended December 31, 2011
	Q1			Q2			Q3			Q4
Revenues	$	1,744		$	7,269		$	1,174		$	11,427
Net loss	$	(18,466	)	$	(10,635	)	$	(15,229	)	$	(4,267	)
Basic and diluted net loss per share	$	(0.16	)	$	(0.09	)	$	(0.12	)	$	(0.03	)
Shares used to compute basic and diluted net loss per share		115,726			117,864			124,069			142,482

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2012 USD ($) Segment	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Number of Operating Segment \| Segment	1
Cash, cash equivalents and marketable securities	$ 125,100
Currency translation adjustments	$ (640)	$ (1,006)
Intangible asset, estimated useful lives	5 years
Number of reporting units \| Segment	1
Unrecognized tax benefits	$ 0
Unrecognized tax benefits, accrued amounts for interest and penalties	$ 0
Employee Stock Option \| Senior Management Group
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Estimated annual forfeiture rate	5.00%
Employee Stock Option \| All Other Employees
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Estimated annual forfeiture rate	13.00%
Maximum
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Cash equivalents original maturity period	3 months
Rhein
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Currency translation adjustments	$ 400	(300)	$ (600)
Currency transaction gain (loss)	$ (200)	$ 200	$ (100)
UNITED STATES
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Percentage of revenue earned	88.00%	94.00%	98.00%
Percentage of long lived assets	10.00%	14.00%

Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	$ 123,588	$ 111,671
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	3,140	17,171
US Government Agencies Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	119,233	28,495
US Treasury Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	500	7,425
Municipal Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	715
Corporate Debt Securities, Secured by the U.S. Government
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets		58,580
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	3,140	17,171
Fair Value, Inputs, Level 1 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	3,140	17,171
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	120,448	94,500
Fair Value, Inputs, Level 2 \| US Government Agencies Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	119,233	28,495
Fair Value, Inputs, Level 2 \| US Treasury Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	500	7,425
Fair Value, Inputs, Level 2 \| Municipal Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	$ 715
Fair Value, Inputs, Level 2 \| Corporate Debt Securities, Secured by the U.S. Government
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets		$ 58,580

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012	Apr. 30, 2010
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash flows discounted rate			16.00%
Common stock shares outstanding as converted basis				10,913,873
April 2010 Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock shares outstanding as converted basis					7,038,210
Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Changes in fair value of contingent consideration liability	$ 9,500
Reclassification of warranty liability into equity	$ 12,000
Contingent Consideration Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Changes in fair value of contingent consideration liability		$ (843)	$ (2,197)
Fair Value, Inputs, Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Estimated fair value of contingent liability		0
Fair Value, Inputs, Level 3 \| Contingent Consideration Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Changes in fair value of contingent consideration liability		$ (800)	$ (2,200)

Changes in Fair Value Measurement of Contingent Liability (Detail) - Contingent Consideration Liabilities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Beginning Balance	$ 843	$ 3,040
Adjustment to fair value measurement	$ (843)	(2,197)
Ending Balance		$ 843

Summary of Cash, Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	$ 125,085	$ 113,964
Unrealized Gains	46	9
Unrealized Losses	(1)	(12)
Estimated Fair Value	125,130	113,961
Cash and Cash Equivalents
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	7,599	31,943
Unrealized Losses		(2)
Estimated Fair Value	7,599	31,941
Cash and Cash Equivalents \| Cash
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	1,542	2,290
Estimated Fair Value	1,542	2,290
Cash and Cash Equivalents \| Money market funds
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	3,140	17,171
Estimated Fair Value	3,140	17,171
Cash and Cash Equivalents \| US Government Agencies Debt Securities
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	715	2,013
Estimated Fair Value	715	2,013
Cash and Cash Equivalents \| Municipal Securities
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	2,202
Estimated Fair Value	2,202
Cash and Cash Equivalents \| US Treasury Securities
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost		7,425
Estimated Fair Value		7,425
Cash and Cash Equivalents \| Corporate Debt Securities, Secured by the U.S. Government
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost		3,044
Unrealized Losses		(2)
Estimated Fair Value		3,042
Available-for-sale Securities
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	117,486	82,021
Unrealized Gains	46	9
Unrealized Losses	(1)	(10)
Estimated Fair Value	117,531	82,020
Available-for-sale Securities \| US Government Agencies Debt Securities
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	116,986	26,488
Unrealized Gains	46
Unrealized Losses	(1)	(5)
Estimated Fair Value	117,031	26,483
Available-for-sale Securities \| US Treasury Securities
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	500
Estimated Fair Value	$ 500
Available-for-sale Securities \| Corporate Debt Securities, Secured by the U.S. Government
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost		55,533
Unrealized Gains		9
Unrealized Losses		(5)
Estimated Fair Value		$ 55,537

Maturities of Marketable Securities Available-for-Sale (Detail) $ in Thousands	Dec. 31, 2012 USD ($)
Amortized cost
Mature in one year or less	$ 79,743
Mature after one year through two years	37,743
Total amortized cost	117,486
Estimated Fair Value
Mature in one year or less	79,772
Mature after one year through two years	37,759
Total estimated fair value	$ 117,531

- Definition

Amount of debt securities categorized neither as held-to-maturity nor trading.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=7534914&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-Subparagraph (b)-(g)
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 137
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15C
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Available-for-Sale Securities - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule of Available-for-sale Securities [Line Items]
Realized gains or losses from the sale of marketable securities	$ 0	$ 0	$ 0

Component of Property and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]
Manufacturing equipment	$ 7,574	$ 7,305
Lab equipment	6,755	6,430
Computer equipment	1,807	1,488
Furniture and fixtures	983	978
Leasehold improvements	5,445	3,989
Assets in progress	1,047	389
Property, Plant and Equipment, Gross, Total	23,611	20,579
Less accumulated depreciation and amortization	(15,646)	(14,416)
Total	$ 7,965	$ 6,163
Manufacturing Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (In years)	5 years
Manufacturing Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (In years)	14 years
Lab Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (In years)	5 years
Lab Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (In years)	13 years
Computer Equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (In years)	3 years
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (In years)	3 years
Leasehold Improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (In years)	5 years
Leasehold Improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (In years)	7 years

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 1,207	$ 1,303	$ 1,415

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References + Details

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	5 years
Amortization of intangible assets		$ 299	$ 980
Manufacturing Process
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	5 years
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	5 years

Component of Current Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Accrued Liabilities Abstract
Payroll and related expenses	$ 4,538	$ 3,224
Legal expenses	396	220
Third party research and development expenses	3,207	3,903
Other accrued liabilities	1,922	812
Accrued liabilities	$ 10,063	$ 8,159

- Definition

Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Symphony Dynamo, Inc. - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended									3 Months Ended	12 Months Ended
	May 09, 2012	Nov. 03, 2011	Nov. 02, 2010	Jun. 30, 2010	Apr. 30, 2010	Apr. 16, 2010	Nov. 30, 2009	Apr. 30, 2007	Apr. 18, 2006	Jun. 30, 2010	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2009
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Warrants issued to purchase common stock					7,038,210		2,000,000
Warrants exercisable period					5 years	5 years	5 years		5 years
Warrants exercise price					$ 1.50	$ 1.50	$ 1.94		$ 7.32
Warrant exercised								$ 15,000
Common stock issue on acquisition							13,000,000
Issued note to Holdings, principal amount							$ 15,000
Principal amount, due date							Dec. 31, 2012
Business acquisition contingent consideration percentage							50.00%
Business acquisition upfront payment							$ 50,000
Net present value model, discount rate											17.00%
Repayment of note payable											$ 15,000
Stock issued during period, shares	17,500,000	27,600,000	26,450,000		1,076,420							900,860	1,281,100
Non operating income expense										$ 11,100
Warrants outstanding											10,913,873
Warrant Liability
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Changes in warrant liability				$ 9,500
Increase in additional paid in capital				1,600
Reclassification of warranty liability into equity				$ 12,000
Maximum
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Warrants issued to purchase common stock									2,000,000
SDI
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Investments in SDI									$ 50,000
Ownership percentage by parent									100.00%
Warrants outstanding											6,765,128
Holdings
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Ownership percentage by parent									100.00%

Financing Agreements - Additional Information (Detail) $ / shares in Units, $ in Millions	1 Months Ended										12 Months Ended
	May 09, 2012 USD ($) $ / shares shares	Nov. 03, 2011 USD ($) $ / shares shares	Nov. 02, 2010 USD ($) $ / shares shares	Sep. 30, 2010 USD ($) shares	Sep. 20, 2010 USD ($)	Apr. 30, 2010 $ / shares shares	Apr. 16, 2010 USD ($) $ / shares shares	Nov. 30, 2009 $ / shares	Aug. 17, 2009 USD ($)	Apr. 18, 2006 $ / shares	Dec. 31, 2012 shares	Dec. 31, 2011 USD ($) shares	Dec. 31, 2010 USD ($) shares	Dec. 31, 2009 USD ($) shares
Other Liabilities [Line Items]
Stock issued during period, shares	17,500,000	27,600,000	26,450,000			1,076,420							900,860	1,281,100
Public offering net price per share \| $ / shares	$ 4.25	$ 2.50	$ 1.70				$ 1.4525
Net proceeds from offering \| $	$ 69.6	$ 64.5	$ 42.0				$ 41.1						$ 1.2	$ 2.3
Sale of stock pursuant to exercise of underwriters overallotment option		3,600,000	3,450,000
Underwriting discount and offering expenses \| $							$ 3.0
Units issued during offering							30,293,000
Warrants exercisable period						5 years	5 years	5 years		5 years
Warrants exercise price \| $ / shares						$ 1.50	$ 1.50	$ 1.94		$ 7.32
Number of shares of common stock in each unit							1
Number of warrants in each unit							1
Number of share per warrant							0.5
Warrants to purchase shares of common stock outstanding											10,913,873
Warrants to purchase common stock											12,700,000
SDI
Other Liabilities [Line Items]
Warrants to purchase shares of common stock outstanding											6,765,128
Maximum
Other Liabilities [Line Items]
Common stock aggregate offering price \| $									$ 15.0
2007 Loan Agreement
Other Liabilities [Line Items]
Warrants to purchase shares of common stock outstanding											1,800,000
Issuance of warrants for common shares to be purchased											3,550,000
2007 Loan Agreement \| Maximum
Other Liabilities [Line Items]
Issuance of warrants for common shares to be purchased											3,550,000
Aspire Capital Fund Llc
Other Liabilities [Line Items]
Stock issued during period, shares												10,995,210	2,350,000
Purchase agreement term					25 months
Percentage of commitment to purchase shares value as commitment fee					4.00%
Commitment fee paid \| $				$ 1.2
Issuance of shares of common stock for commitment fee				600,000
Proceeds from Issuance of Common Stock \| $												$ 26.7	$ 3.3
Aspire Capital Fund Llc \| Maximum
Other Liabilities [Line Items]
Commitment to purchase shares value \| $					$ 30.0

Warrants Issued to Purchase Common Stock (Detail)	12 Months Ended
Warrants Issued to Purchase Common Stock (Detail)	Dec. 31, 2012 $ / Right shares
Class of Warrant or Right [Line Items]
Outstanding	10,913,873
2007 Loan Agreement
Class of Warrant or Right [Line Items]
Shares Issuable	3,550,000
Outstanding	1,800,000
Warrant One \| 2007 Loan Agreement
Class of Warrant or Right [Line Items]
Warrant Issuance Date	Jul. 18, 2007
Shares Issuable	1,250,000
Expiration Date	Feb. 26, 2014
Exercise Price per Share \| $ / Right	5.13
Outstanding	1,250,000
Warrant Two \| 2007 Loan Agreement
Class of Warrant or Right [Line Items]
Warrant Issuance Date	Oct. 18, 2007
Shares Issuable	1,300,000
Expiration Date	Feb. 26, 2014
Exercise Price per Share \| $ / Right	1.68
Outstanding	250,000
Warrant Three \| 2007 Loan Agreement
Class of Warrant or Right [Line Items]
Warrant Issuance Date	Dec. 27, 2007
Shares Issuable	300,000
Expiration Date	Feb. 26, 2014
Exercise Price per Share \| $ / Right	5.65
Outstanding	300,000
Warrant Four \| 2007 Loan Agreement
Class of Warrant or Right [Line Items]
Warrant Issuance Date	Dec. 27, 2007
Shares Issuable	700,000
Expiration Date	Feb. 26, 2014
Exercise Price per Share \| $ / Right	1.68

Commitments and Contingencies - Additional Information (Detail) $ in Thousands, € in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2004 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2012 EUR (€)
Loss Contingencies [Line Items]
Rent expense, net		$ 1,700	$ 1,700	$ 2,600
Deferred rent		600	$ 600
Future minimum payment excluding sub lease agreement payment		41
Cash, cash equivalents and marketable securities		125,100
Future payments obligation		$ 9,900
Deutsche Bank Securities
Loss Contingencies [Line Items]
Letter of credit pledged as security \| €					€ 0.2
Berkeley, California (the "Berkeley Lease")
Loss Contingencies [Line Items]
Operating leases expiration date		2018-06
Letter of credit pledged as security	$ 400
Terms of the lease	If the total amount of our cash, cash equivalents and marketable securities falls below $20 million for a period of more than 30 consecutive days during the lease term, the amount of the required security deposit will increase to $1.1 million, until such time as our projected cash and cash equivalents will exceed $20 million for the remainder of the lease term, or until our actual cash and cash equivalents remains above $20 million for a period of 12 consecutive months.
Berkeley, California (the "Berkeley Lease") \| Contingency, A
Loss Contingencies [Line Items]
Increase in amount of the security deposit	$ 1,100
Berkeley, California (the "Berkeley Lease") \| Contingency, A \| Maximum
Loss Contingencies [Line Items]
Cash, cash equivalents and marketable securities	$ 20,000
Berkeley, California (the "Berkeley Lease") \| Contingency, A \| Minimum
Loss Contingencies [Line Items]
Contingency period for cash, cash equivalents and marketable securities	30 days
Berkeley, California (the "Berkeley Lease") \| Contingency, B
Loss Contingencies [Line Items]
Contingency period for cash, cash equivalents and marketable securities	12 months
Berkeley, California (the "Berkeley Lease") \| Contingency, B \| Minimum
Loss Contingencies [Line Items]
Cash, cash equivalents and marketable securities	$ 20,000
Dusseldorf, Germany (the "Dusseldorf Lease")
Loss Contingencies [Line Items]
Operating leases expiration date		2023-03

Future Minimum Payments under Non-Cancelable Portion of Operating Leases (Detail) $ in Thousands	Dec. 31, 2012 USD ($)
Operating Leased Assets [Line Items]
2013	$ 2,064
2014	2,210
2015	2,260
2016	2,311
2017	2,360
Thereafter	3,727
Total	$ 14,932

Collaborative Research, Development, and License Agreements - Additional Information (Detail) $ in Thousands	1 Months Ended					3 Months Ended		12 Months Ended
	Oct. 31, 2011 USD ($)	Mar. 31, 2010 USD ($)	Dec. 31, 2008 USD ($) Project	Sep. 30, 2008 USD ($)	Sep. 30, 2006 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2008 USD ($)	Jun. 30, 2012 USD ($)	May 31, 2012 USD ($)	Jul. 31, 2011 USD ($)	Aug. 31, 2010 USD ($)	Jul. 31, 2010 USD ($)	Jul. 31, 2008 USD ($)
Glaxo, Smith, Kline
Product Information [Line Items]
Number of programs for research and early clinical development \| Project			4
Collaboration revenue			$ 10,000					$ 1,428	$ 1,428	$ 1,428
Revenue from milestone payment									15,000
Deferred revenue recognition period						7 years		7 years
Deferred revenue						$ 4,200		$ 4,200	5,700
Astra Zeneca
Product Information [Line Items]
Collaboration revenue					$ 10,000			720	120	10,778
Revenue from milestone payment								$ 2,462	642	$ 3,315	$ 4,500
Deferred revenue recognition period						50 months		50 months
Deferred revenue						$ 7,700		$ 7,700	4,900
Research collaboration and license agreement period					3 years
Astra Zeneca \| Amendment
Product Information [Line Items]
Collaboration revenue	$ 3,000
Cost of clinical development activities									$ 20,000
Astra Zeneca \| Amendment \| Advance the program following completion of Phase 2a
Product Information [Line Items]
Collaboration revenue						6,000	$ 2,600
Revenue from milestone payment						$ 20,000
National Institutes of Health \| Rheumatoid Arthiritis
Product Information [Line Items]
Grants receivable													$ 400
National Institutes of Health \| Autoimmune Disease
Product Information [Line Items]
Grants receivable												$ 600
National Institutes of Health \| Skin Autoimmune Inflammation
Product Information [Line Items]
Grants receivable														$ 600
National Institutes of Health \| HBV
Product Information [Line Items]
Grants receivable															$ 1,100
National Institutes of Health \| HPV
Product Information [Line Items]
Grants receivable																$ 600
National Institutes of Health \| ISS Technology
Product Information [Line Items]
Contract agreement period				5 years
Contract awarded to develop technology				$ 17,000
National Institutes of Health \| SLE
Product Information [Line Items]
Grants receivable																	$ 1,800
Merck \| HBV
Product Information [Line Items]
Collaboration revenue		$ 4,000

Summary of Revenue Earned under Agreement with GSK (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended								12 Months Ended
	Dec. 31, 2008	Sep. 30, 2006	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2008
Product Information [Line Items]
Total			$ 1,806	$ 2,874	$ 2,684	$ 2,350	$ 11,427	$ 1,174	$ 7,269	$ 1,744	$ 9,714	$ 21,614	$ 23,950
Grant revenue											3,939	3,110	3,940
National Institute Of Allergy And Infectious Diseases
Product Information [Line Items]
Grant revenue											3,571	2,730	3,197
Glaxo, Smith, Kline
Product Information [Line Items]
Initial payment	$ 10,000										1,428	1,428	1,428
Milestone revenue												15,000
Total											1,428	16,428	1,428
Astra Zeneca
Product Information [Line Items]
Initial payment		$ 10,000									720	120	10,778
Milestone revenue											2,462	642	3,315	$ 4,500
Total											3,182	762	14,093
National Institutes of Health
Product Information [Line Items]
Grant revenue											$ 368	$ 380	$ 743

Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Basic and diluted net loss per share (in thousands, except per share amounts):
Net loss	$ (20,543)	$ (17,791)	$ (15,110)	$ (16,505)	$ (4,267)	$ (15,229)	$ (10,635)	$ (18,466)	$ (69,949)	$ (48,597)	$ (57,308)
Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding	180,685	177,870	167,697	155,431	142,482	124,069	117,864	115,726	170,469	125,101	82,463
Basic and diluted net loss per share	$ (0.11)	$ (0.10)	$ (0.09)	$ (0.11)	$ (0.03)	$ (0.12)	$ (0.09)	$ (0.16)	$ (0.41)	$ (0.39)	$ (0.69)
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Outstanding securities not included in diluted net loss per share calculation									28,275	36,830	33,022
Stock Options and Stock Awards
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Outstanding securities not included in diluted net loss per share calculation									15,561	11,101	7,288
Warrant
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Outstanding securities not included in diluted net loss per share calculation									12,714	25,729	25,734

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Millions	1 Months Ended					3 Months Ended		12 Months Ended
	Jan. 31, 2011 shares	Jan. 31, 2010 shares	Nov. 04, 2008 $ / shares $ / Item	Jan. 31, 2004 shares	Jan. 31, 1997 shares	Dec. 31, 2012 USD ($) CompensationPlan $ / shares shares	Mar. 31, 2007 shares	Dec. 31, 2012 USD ($) CompensationPlan $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2010 USD ($) $ / shares	Mar. 31, 2010 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share-based compensation plans \| CompensationPlan						4		4
Expiration period									10 years
Options vesting period									4 years
Number of shares of Common Stock outstanding						13,806,000		13,806,000	10,987,000
Total intrinsic value of options exercised \| $								$ 2.7	$ 0.1	$ 0.1
Total fair Value of Stock Options Vested \| $								$ 9.6	$ 2.8		$ 4.1
Options and restricted stock units outstanding								2,617,966
Expected dividend yield								0.00%
Total unrecognized compensation cost related to non-vested equity awards \| $						$ 0.3		$ 0.3
Warrants to purchase common stock						10,913,873		10,913,873
Common stock par value per share \| $ / shares			$ 0.001			$ 0.001		$ 0.001	$ 0.001
Dividends payable date			Nov. 17, 2008
Preferred shares par value per share \| $ / shares			$ 0.001			$ 0.001		$ 0.001	$ 0.001
Preferred shares price \| $ / Item			6.00
Rights expiration date			Nov. 17, 2018
Additional
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation \| $						$ 1.5
Equity Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards \| $						6.3		$ 6.3
Time Based Vesting Schedule
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards \| $						14.3		$ 14.3
Total unrecognized compensation cost, weighted-average vesting period								2 years 3 months 18 days
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards \| $						$ 0.3		$ 0.3
Total unrecognized compensation cost, weighted-average vesting period								1 year
Senior Management Group
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)								6 years
All Other Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)								5 years 6 months
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of common shares outstanding			20.00%
Percentage of assets			50.00%
Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common stock						12,700,000		12,700,000
Warrants exercised								13,000,000	4,500,000
Warrant \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercisable per share \| $ / shares								$ 5.65
Warrant \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercisable per share \| $ / shares								$ 1.50
Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Based Compensation expense related to restricted stock \| $								$ 0.2
Aggregate Intrinsic Value \| $						$ 5.0		$ 5.0
Grant date fair value of Restricted Stock \| $ / shares								$ 4.23	$ 0.00	$ 1.98
Total fair value of restricted stock units \| $								$ 0.2	$ 0.8	$ 0.0
1997 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options previously available for grant Expired							273,188
Number of shares of Common Stock outstanding						471,788		471,788
1997 Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock shares					3,443,630
Expiration period					10 years
1997 Plan \| Non Employee Stock Options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period					4 years
1997 Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option exercise price as percentage of fair value of shares on day of grant					85.00%
1997 Plan \| Stock Options \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period					4 years
1997 Plan \| ISOs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option exercise price as percentage of fair value of shares on day of grant					100.00%
1997 Plan \| ISOs \| 10% stockholder
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option exercise price as percentage of fair value of shares on day of grant					110.00%
Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of Common Stock outstanding						779,000		779,000
Inducement Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock shares		1,500,000
2011 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Number of shares of Common Stock outstanding						8,257,406		8,257,406
2011 Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock shares	15,000,000
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved and approved for issuance						996,000		996,000
Shares issued to employees								698,724
Shares remaining available for future purchases						297,276		297,276
Employee Stock Purchase Plan \| The commencement of the offer period (generally, the fifteenth day in February or August)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price per share as percentage of fair market value of common stock				85.00%
Employee Stock Purchase Plan \| The exercise date, which is the last day of a purchase period (generally, the fourteenth day in February or August)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price per share as percentage of fair market value of common stock				85.00%
2004 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option exercise price as percentage of fair value of shares on day of grant				100.00%
Number of shares of Common Stock outstanding						4,298,027		4,298,027
2004 Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock shares				3,500,000
2004 Plan \| Stock possessing more than 10% of the voting power of all classes of the Company's stock or the stock of any parent or subsidiary of the Company \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period				5 years
Option exercise price as percentage of fair value of shares on day of grant				110.00%
2004 Plan \| Other Participants \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period				10 years

Activity under Stock Plans (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2012 USD ($) $ / shares shares
Number of Options Outstanding
Number of share outstanding beginning balance \| shares	10,987
Options granted \| shares	4,534
Options exercised \| shares	(1,166)
Ending balance \| shares	13,806
Vested and expected to vest at December 31, 2012 \| shares	12,886
Exercisable at December 31, 2012 \| shares	7,226
Weighted-Average Price Per Share
Beginning balance \| $ / shares	$ 3.10
Options granted \| $ / shares	3.68
Options exercised \| $ / shares	1.79
Ending Balance \| $ / shares	3.38
Vested and expected to vest \| $ / shares	3.37
Exercisable at December 31, 2012 \| $ / shares	$ 3.49
Weighted Average Remaining Contractual Life (In years)
Weighted average remaining contractual life (in years)	7 years 3 months 4 days
Outstanding options vested and expected to vest	7 years 1 month 17 days
Options exercisable	5 years 10 months 28 days
Aggregate Intrinsic Value
Granted \| $	$ 4,015
Outstanding options (vested and expected to vest) \| $	3,955
Options exercisable \| $	$ 2,825
Unvested
Number of Options Outstanding
Options cancelled \| shares	(505)
Weighted-Average Price Per Share
Options cancelled \| $ / shares	$ 3.32
Vested
Number of Options Outstanding
Options cancelled \| shares	(44)
Weighted-Average Price Per Share
Options cancelled \| $ / shares	$ 5.53

Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Unit - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Number of shares
Beginning Balance	115
Granted	1,815
Vested	(115)
Forfeited or expired	(60)
Ending Balance	1,755	115
Weighted Average Grant Date Fair Value
Beginning Balance	$ 1.98
Granted	4.23	$ 0.00	$ 1.98
Vested	1.98
Forfeited or expired	4.22
Ending Balance	$ 4.23	$ 1.98

Black-Scholes Valuation Model and Weighted-Average Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per share, options	$ 3.30	$ 2.76	$ 1.49
Risk-free interest rate	0.50%	1.30%	1.70%
Expected life (in years)	4 years 2 months 12 days	4 years	4 years
Volatility	1.60%	1.60%	1.60%
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per share, options	$ 3.53	$ 2.09	$ 1.47
Risk-free interest rate	0.20%	0.30%	0.40%
Expected life (in years)	1 year 1 month 6 days	1 year 2 months 12 days	10 months 24 days
Volatility	1.60%	1.60%	1.60%

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share Based Compensation	$ 10,439	$ 5,189	$ 2,410
Employee and Director Stock-Based Compensation Expense
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share Based Compensation	10,439	5,185	2,378
Non-Employees Stock-Based Compensation Expense
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share Based Compensation		4	32
Research and Development Expense
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share Based Compensation	3,514	2,103	632
General and Administrative Expense
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share Based Compensation	$ 6,925	$ 3,086	$ 1,778

Component of Consolidated Income (Loss) Before Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items]
U.S.	$ (70,792)	$ (49,990)	$ (56,379)
Non U.S.	843	1,393	(929)
Total	$ (69,949)	$ (48,597)	$ (57,308)

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax Disclosure [Line Items]
Income tax expense
Increase (decrease) in valuation allowance	22.0	$ 18.1	19.9
Amount of valuation allowance for deferred tax assets allocated to contributed capital	0.4
Other income			$ 0.7
Federal
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 323.8
Federal \| Minimum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2018
Federal \| Maximum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2032
Federal \| Research And Development
Income Tax Disclosure [Line Items]
Tax credit carryforward amount	$ 11.2
Federal \| Research And Development \| Minimum
Income Tax Disclosure [Line Items]
Tax credit carryforward amount, expiration year	2018
Federal \| Research And Development \| Maximum
Income Tax Disclosure [Line Items]
Tax credit carryforward amount, expiration year	2032
California State
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 226.2
California State \| Minimum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2013
California State \| Maximum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2032
California State \| Research And Development
Income Tax Disclosure [Line Items]
Tax credit carryforward amount	$ 10.5
Foreign
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 28.0

Difference between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax Rate Reconciliation [Line Items]
Income tax benefit at federal statutory rate	$ (23,650)	$ (16,523)	$ (19,486)
State tax	(89)	(2,586)	(1,617)
Tax credits		(1,394)	(2,172)
Deferred compensation charges	1,002	595	318
Change in valuation allowance	21,966	18,099	19,863
Change in foreign tax rates		(34)	22
Change in the fair value measurements		286	2,997
Non-deductible debt discount		509	420
Deemed dividend		273
Other	771	775	(345)
Total income tax expense

Component of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets:
Net operating loss carry forwards	$ 127,529	$ 103,119
Research tax credit carry forwards	18,163	17,477
Accruals and reserves	8,529	6,818
Capitalized research costs	12,757	17,278
Deferred revenue	2,180	2,189
Other	1,221	1,455
Deferred Tax Assets, Gross, Total	170,379	148,336
Less valuation allowance	(170,232)	(148,266)
Total deferred tax assets	147	70
Deferred tax liabilities:
Acquired intangible assets	(86)	(27)
Other	(61)	(43)
Total deferred tax liabilities	(147)	(70)
Net deferred tax assets

Selected Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Selected Quarterly Financial Data [Line Items]
Revenues	$ 1,806	$ 2,874	$ 2,684	$ 2,350	$ 11,427	$ 1,174	$ 7,269	$ 1,744	$ 9,714	$ 21,614	$ 23,950
Net loss	$ (20,543)	$ (17,791)	$ (15,110)	$ (16,505)	$ (4,267)	$ (15,229)	$ (10,635)	$ (18,466)	$ (69,949)	$ (48,597)	$ (57,308)
Basic and diluted net loss per share	$ (0.11)	$ (0.10)	$ (0.09)	$ (0.11)	$ (0.03)	$ (0.12)	$ (0.09)	$ (0.16)	$ (0.41)	$ (0.39)	$ (0.69)
Shares used to compute basic and diluted net loss per share	180,685	177,870	167,697	155,431	142,482	124,069	117,864	115,726	170,469	125,101	82,463

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details